0001079973-22-000915.txt : 20220801 0001079973-22-000915.hdr.sgml : 20220801 20220801161406 ACCESSION NUMBER: 0001079973-22-000915 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220801 DATE AS OF CHANGE: 20220801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MediXall Group, Inc. CENTRAL INDEX KEY: 0001601280 STANDARD INDUSTRIAL CLASSIFICATION: RAILROADS, LINE-HAUL OPERATING [4011] IRS NUMBER: 330864127 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-194337 FILM NUMBER: 221124894 BUSINESS ADDRESS: STREET 1: 2929 EAST COMMERCIAL BLVD STREET 2: PH-D CITY: FT LAUDERDALE STATE: FL ZIP: 33308 BUSINESS PHONE: 954-440-4678 MAIL ADDRESS: STREET 1: 2929 EAST COMMERCIAL BLVD STREET 2: PH-D CITY: FT LAUDERDALE STATE: FL ZIP: 33308 FORMER COMPANY: FORMER CONFORMED NAME: CONTINENTAL RAIL CORP DATE OF NAME CHANGE: 20140227 10-Q 1 mdxl_10q-033122.htm FORM 10-Q
0001601280 false 12/31 2022 Q1 0001601280 2022-01-01 2022-03-31 0001601280 2022-08-01 0001601280 2022-03-31 0001601280 2021-12-31 0001601280 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001601280 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001601280 us-gaap:SeriesBPreferredStockMember 2022-03-31 0001601280 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001601280 2021-01-01 2021-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2020-12-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2020-12-31 0001601280 us-gaap:CommonStockMember 2020-12-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001601280 us-gaap:RetainedEarningsMember 2020-12-31 0001601280 2020-12-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-12-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-12-31 0001601280 us-gaap:CommonStockMember 2021-12-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001601280 us-gaap:RetainedEarningsMember 2021-12-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-01-01 2021-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-01-01 2021-03-31 0001601280 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001601280 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2022-01-01 2022-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2022-01-01 2022-03-31 0001601280 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001601280 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-03-31 0001601280 us-gaap:CommonStockMember 2021-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001601280 us-gaap:RetainedEarningsMember 2021-03-31 0001601280 2021-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2022-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2022-03-31 0001601280 us-gaap:CommonStockMember 2022-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001601280 us-gaap:RetainedEarningsMember 2022-03-31 0001601280 us-gaap:CommonStockMember mdxl:MediXallGroupIncMember 2022-01-01 2022-01-17 0001601280 2022-01-17 0001601280 mdxl:MediXallGroupIncMember 2022-01-01 2022-01-17 0001601280 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001601280 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-03-31 0001601280 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001601280 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0001601280 mdxl:SeniorConvertibleDebenturesAndWarrantsMember 2022-01-01 2022-03-31 0001601280 mdxl:SeniorConvertibleDebenturesAndWarrantsMember 2021-01-01 2021-03-31 0001601280 us-gaap:SeriesBPreferredStockMember 2020-06-24 0001601280 mdxl:TBGMember 2022-01-01 2022-03-31 0001601280 2021-04-01 2021-04-30 0001601280 mdxl:TBGMember 2021-01-01 2021-03-31 0001601280 mdxl:TBGMember 2022-03-31 0001601280 mdxl:TBGMember 2021-12-31 0001601280 mdxl:R3AccountingLLCMember 2022-01-01 2022-03-31 0001601280 mdxl:R3AccountingLLCMember 2021-01-01 2021-03-31 0001601280 mdxl:TBGHoldingsCorpMember 2022-03-31 0001601280 mdxl:TBGHoldingsCorpMember 2021-12-31 0001601280 mdxl:TurnkeyMember 2022-03-31 0001601280 mdxl:TurnkeyMember 2021-12-31 0001601280 mdxl:R3AccountingLLCMember 2022-03-31 0001601280 mdxl:R3AccountingLLCMember 2021-12-31 0001601280 2022-03-01 2022-03-31 0001601280 mdxl:ThreeConvertibleLoanDebenturesMember 2022-03-31 0001601280 mdxl:ThreeConvertibleLoanDebenturesMember 2022-03-01 2022-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________________to__________________________

 

Commission File Number: 333-194337

 

MediXall Group, Inc.

 (Exact name of registrant as specified in its charter)

 

Nevada 33-0864127
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification Number)
   

2929 East Commercial Blvd., PH-D,

Ft. Lauderdale, Florida

 33308
(Address of principal executive offices) (Zip Code)

 

954-440-4678

(Registrant’s telephone number, including area code)

 

Not applicable

 (Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ¨ Accelerated filer   ¨
Non-accelerated filer    ☒ Smaller reporting company ☒
  Emerging growth company  ¨

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of August 1, 2022, the issuer had 118,134,789 shares of its common stock issued and outstanding.

 

 

 

 
 

 

MEDIXALL GROUP, INC. AND SUBSIDIARIES

 

INDEX

 

    Page No.
PART I FINANCIAL INFORMATION  
     
ITEM 1. FINANCIAL STATEMENTS: 1
  Condensed Consolidated Balance Sheets at March 31, 2022 (unaudited) and December 31, 2021 1
  Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 (unaudited) 2
  Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three months ended March 31, 2022 and 2021 (unaudited) 3
  Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021 (unaudited) 4
  Notes to Condensed Consolidated Financial Statements (unaudited) 5
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 12
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 16
ITEM 4. CONTROLS AND PROCEDURES 16
     
PART II OTHER INFORMATION  
     
ITEM 1. LEGAL PROCEEDINGS 18
ITEM 1A. RISK FACTORS 18
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 18
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 18
ITEM 4. MINE SAFETY DISCLOSURES 18
ITEM 5. OTHER INFORMATION 18
ITEM 6. EXHIBITS 19
SIGNATURES 20

 

 

 

 

 
 

 

PART I.  FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENDSED CONSOLIDATED BALANCE SHEETS

 

           
   March 31,   December 31, 
   2022   2021 
    (Unaudited)     
ASSETS        
CURRENT ASSETS:          
Cash  $103,900   $63,418 
Prepaid expenses - related party   116,413    276,043 
Other assets   7,484    3,484 
  Total current assets   227,797    342,945 
           
Furniture and equipment, net   20,696    23,376 
Rights-to-use-intellectual property   227,571    —   
Right-of-use-operating lease asset   295,963    313,856 
Website and development costs   453,084    451,404 
           
    Total assets  $1,225,111   $1,131,581 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
           
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $585,720   $588,870 
Accounts payable and accrued expenses - related party   589,202    567,202 
Operating lease liability   60,189    69,258 
           
        Total current liabilities   1,235,111    1,225,330 
           
Operating lease liability, net of current portion   238,615    246,373 
Senior Convertible Debentures, net of discount of $23,800   426,880    —   
           
Total liabilities   1,900,606    1,471,703 
           
STOCKHOLDERS' DEFICIT:          
Convertible Preferred Series A stock, $0.001 par value, 1,000,000 authorized; 264,894 issued and outstanding   265    265 
Convertible Preferred Series B stock, $0.001 par value, 4,000,000 authorized; 3,909,360 issued and outstanding   3,909    3,909 
Common Stock, $0.001 par value 750,000,000 shares authorized; 115,901,920 and 110,864,595 shares issued and outstanding   115,901    110,864 
Additional paid-in capital   27,396,922    25,327,230 
Accumulated deficit   (28,192,492)   (25,782,390)
           
Total stockholders' deficit   (675,495)   (340,122)
           
Total liabilities and stockholders' deficit  $1,225,111   $1,131,581 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

1 
 

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

 

 

           
   Three Months Ended 
   March 31, 
   2022   2021 
         
Revenue  $7,907   $3,271 
           
Operating Expenses          
    Professional fees   328,657    339,580 
    Professional fees - related party   120,000    164,038 
    Management fees - related party   240,000    120,000 
    Personnel related expenses   1,529,954    601,550 
    Other selling, general and administrative   199,398    110,404 
        Total Operating Expenses   2,418,009    1,335,572 
Loss before income taxes   (2,410,102)   (1,332,301)
Income taxes   —      —   
Net loss   (2,410,102)   (1,332,301)
           
Less preferred stock dividends   72,840    46,969 
           
Net loss to common shareholders  $(2,482,942)  $(1,379,270)
           
Net loss per common share - basic and diluted  $(0.02)  $(0.01)
           
Weighted average number of common shares outstanding during the periods - basic and diluted   114,625,809    100,242,517 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

2 
 

 

 

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

 

 

                                              
   Series A Voting   Series B Voting                   Total 
   Preferred Stock   Preferred Stock   Common Stock   Additional       Stockholders' 
   $0.001 Par Value   $0.001 Par Value   $0.001 Par Value   Paid-in   Accumulated   Equity 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   (Deficit) 
                                     
Balance, December 31 2020   264,894    265    1,639,360    1,639    98,898,130    98,898    19,862,918    (19,581,816)   381,904 
                                              
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs   —      —      —      —      2,487,550    2,488    619,387    —      621,875 
Proceeds received from sale of Preferred Stock   —      —      1,345,000    1,345    —      —      1,343,655    —      1,345,000 
Net loss   —      —      —      —      —      —      —      (1,332,301)   (1,332,301)
Balance, March 31 2021 (Unaudited)   264,894    265    2,984,360    2,984    101,385,680    101,386    21,825,960    (20,914,117)   1,016,478 
                                              
Balance, December 31 2021   264,894    265    3,909,360    3,909    110,864,595    110,864    25,327,230    (25,782,390)   (340,122)
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs   —      —      —      —      1,800,000    1,800    718,200    —      720,000 
Common stock issued for services   —      —      —      —      2,737,325    2,737    1,092,192    —      1,094,929 
Common stock issued in exchange for right-to-use intellectual property   —      —      —      —      500,000    500    235,500    —      236,000 
Fair value of Warrants issued with Convertible Debentures   —      —      —      —      —      —      23,800    —      23,800 
Net loss   —      —      —      —      —      —      —      (2,410,102)   (2,410,102)
Balance, March 31 2022 (Unaudited)   264,894    265    3,909,360    3,909    115,901,920    115,901    27,396,922    (28,192,492)   (675,495)

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

3 
 

 

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

 

 

           
   Three Months Ended
March 31,		 
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(2,410,102)  $(1,332,301)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   2,680    1,000 
Common stock issued as compensation for services   1,094,929    —   
Amortization of debenture discounts    680    —   
Changes in operating assets and liabilities:          
Other assets   (4,000)   (45,933)
Prepaid expenses - related party   159,630    —   
Accounts payable and accrued expenses   (3,150)   82,030 
Accounts payable and accrued expenses - related party   22,000    —   
Amortization of right-of-use operating lease asset   17,893    18,232 
Amortization of right-to-use intellectual property   8,429    —   
Operating lease liability   (16,827)   (19,208)
Net cash used in operating activities   (1,127,838)   (1,296,180)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Website and development costs   (1,680)   —   
Net cash used in investing activities   (1,680)   —   
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from the sale of common stock, net of offering costs   720,000    621,875 
Proceeds from the sale of preferred stock   —      1,345,000 
Proceeds from issuance of convertible debentures   450,000    —   
Net cash provided by financing activities   1,170,000    1,966,875 
           
Net increase in cash   40,482    670,695 
Cash at beginning of period   63,418    645,762 
           
Cash at end of period  $103,900   $1,316,457 
           
Supplemental Disclosure of Cash Flow Information:          
Issuance of Common Stock in exchange for of the Right-to-Use Intellectual Property  $236,000    —   
Discount issued with Convertible Debentures  $23,800    —   

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

4 
 

 

MEDIXALL GROUP, INC. AND SUBSIDIARIES

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

Note 1 - Organization and Nature of Operation

 

MediXall Group, Inc. (the "Company “or “MediXall”) was incorporated on December 21, 1998 under the laws of the State of Nevada under the name of IP Gate, Inc. The Company had various name changes since, to reflect changes in the Company’s operating strategies.

 

MediXall Group, Inc. (OTCQB:MDXL) is an innovation-driven technology company purposefully designed and structured around delivering products and services to help consumers learn, decide, and pay for healthcare in ways that complement relationships with trusted doctors. The mission of MediXall Group is to revolutionize the medical industry--improve communication, provide better technology and support services, and provide more efficient, cost-effective healthcare for the consumer. The Company generated minimal revenue in 2022 and 2021 as its online healthcare platform is still in the application and development stage. Further discussion on our operations, mission, and initiatives can be found in the Management’s Discussion and Analysis section of this report.

 

The Company has the following wholly-owned subsidiaries: (1) IHL of Florida, Inc., which is dormant, (2) Medixall Financial Group, which is dormant, (3) Medixaid, Inc., and (4) MediXall.com, Inc., which were established to carry out the development and operation of our healthcare marketplace platform, (5) Health Karma, Inc. which was established in 2020 to increase functionality of the MediXall platform.

 

Note 2 – Asset Acquisition

 

On January 17, 2022, the Company entered into an agreement to acquire the right to use the intellectual property of 24 Hr Virtual Clinic, LLC (“Virtual Clinic”). In connection with the transaction, the Company issued 500,000 shares of common stock of MediXall. In accordance with Accounting Standards Codifiation (“ASC”) 805, the value of the stock issued was measured based on an independent appraisal of the rights to use the intellectual property valued at $236,000, which was determined to be the more clearly determinable measure of fair value.

 

Pursuant to the agreement, the Company has the right to buyout the existing members of the Virtual Clinic for an additional 500,000 shares of MediXall. If this transaction occurs the Virtual Clinic will be renamed to “Wellcare First” and become a wholly-owned subsidiary of the Company.

 

 

Note 3 – Going Concern

 

The Company had an accumulated deficit of $28,192,492 at March 31, 2022, and does not have sufficient operating cash flows. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.

 

Since the Company has generated minimal revenues from its planned operations, its ability to continue as a going concern is wholly dependent upon its ability to obtain additional financing. Since inception, the Company has funded operations through short-term borrowings, related party loans, and the proceeds from equity sales in order to meet its strategic objectives. The Company's future operations are dependent upon its ability to generate revenues along with additional external funding as needed. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business plan. Subsequent to March 31, 2022, the Company has issued 1,800,000 common shares for total proceeds of $720,000.

 

In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These condensed consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. 

 
5 
 

  

 

 Note 4 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the Securities and Exchange Commission (“SEC”) rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Company’s condensed consolidated financial position as of March 31, 2022 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2022. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on April 19, 2022.

 

Principles of Consolidation

 

These unaudited condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

 

Use of Estimates

 

The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.

 

A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustments are reflected in current operations.

 

Subsequent Events

 

Management has evaluated events occurring subsequent to the unaudited condensed consolidated balance sheet date, through August 1, 2022, which is the date the unaudited condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.

 
6 
 

 

Risks and Uncertainties

 

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces significant risk and uncertainty related to the coronavirus global pandemic (“COVID-19”) pandemic.

 

Income Taxes

 

The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification 740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the year that includes the enactment date.

 

Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

 

The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of March 31, 2022. Accordingly, a valuation allowance was recorded against the net deferred tax asset.

 

Revenue Recognition

 

The Company accounts for revenue in accordance with Accounting Standards Updated ("ASU") ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU (collectively, "ASC 606"). The Company had minimal revenues in 2022 and in 2021. The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

 

In 2022 and 2021, the Company generated revenues from selling bundle medical and wellness services to individuals, employer groups, or third-party administrators from the Company’s Health Karma platform. The Company primarily generates revenue from employer customers and consumer subscription fees, which are typically a 12-month commitment in nature. Through our per-Member-per-month (“PMPM”) subscription model, we enter into contracts with our employer customers that pay a fixed monthly rate based on the total number of members. In most cases, members and their dependents have unlimited access to our platform and do not pay extra fees for increased utilization, unless they wish to access services outside the scope of those covered by the subscription.  Our performance obligations are satisfied overtime as we provide access to the Health Karma portal and associated benefits. We recognize revenue monthly as the services are rendered and performance obligations are satisfied.

 

Senior Convertible Debentures and Warrants

 

The senior convertible debentures (Convertible Debt) is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant.

 

Warrants issued with the Convertible Debt are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. The warrant was determined to not have derivative features, and was recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the Convertible Debt. The warrants relative fair values is recorded as a discount to the Convertible Debt and as additional paid-in-capital. Discount on the Convertible Debt is amortized to interest expense over the life of the debt.

 
7 
 

 

Share-Based Payment Arrangements

 

The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

 

Loss Per Share

 

The computation of basic loss per share (“LPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive due to net loss for the periods.

 

Following is the computation of basic and diluted loss per share for the three month periods ended March 31, 2022 and 2021:

 

          
   Three Months Ended 
   March 31, 
   2022   2021 
Basic and Diluted LPS Computation          
Numerator:          
Net loss  $(2,410,102)  $(1,332,301)
Series B Preferred Stock Dividends   72,840    46,969 
           
Loss available to common stockholders  $(2,482,942)  $(1,379,270)
           
Denominator:          
Weighted average number of common shares outstanding  $(0.02)  $(0.01)
           
Basic and diluted LPS   114,625,809    100,242,517 

 

Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

 

          
Series A Preferred stock (convertible)   24,900,000    24,900,000 
Series B Preferred stock (convertible)   15,637,440    11,937,440 
Senior Convertible Debentures and Warrants   382,500    —   

 

Recoverability of Long-Lived Assets

 

The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the three periods ended March 31, 2022 and 2021. However, there can be no assurances that future impairment tests will not result in a charge to operations.

  
8 
 

 

Rights-to-use Intellectual Property

 

The rights-to-use intellectual property (“Intellectual Property”) is an intangible asset arising from the Company’s right to use the proprietary technology and programs of the Virtual Clinic. The Intellectual Property was initially measured at fair value and will be amortized on a straightline basis over its estimated useful life as the economic benefits are consumed or otherwise realized. Management has determined the estimated useful life to be seven years.

 

Website and Development Costs

 

Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of March 31, 2022 and December 31, 2021, the Company has met the capitalization requirements and has incurred $453,084 and $451,404, respectively, in costs related to the development of the MediXall platform. Upon completion, the related assets will be amortized over the estimated useful life of the underlying product. The Company will amortize the cost of the intangible asset using amortization methods that reflect the pattern in which the economic benefits of the intangible asset are consumed or otherwise realized.

 

Allowance for Uncollectible Accounts Receivable

 

An allowance for uncollectible accounts receivable is recorded when management believes the uncollectability of the accounts receivable is confirmed. Subsequent recoveries, if any, are credited to the allowance. The allowance is determined based on management’s review of the debtor’s ability to repay and repayment history, aging history, and estimated value of collateral, if any.

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

 

 

NOTE 5 - Right-to-use Intellectual Property

 

Right-to-use Intellectual Property consists of the following:

 

     
Balances, March 31, 2022     
Gross  $ 236,000 
Accumulated amortization   (8,429)
Net carrying amount  $227,571 

 

Estimated amortization expense for the right-to-use intellectual property for each of the future years ending December 31, is as follows:

 

      
2022 (nine months)   $25,286 
2023    33,714 
2024    33,714 
2025    33,714 
2026    33,714 
Thereafter    67,429 
Total   $227,571 

 

 

 
9 
 

 

Note 6 – Preferred Stock

 

The 264,894 outstanding Series A preferred shares are convertible into 24,900,000 common shares. The preferred shares do not pay dividends. The number of votes for the preferred shares shall be the same as the amount of shares of common shares that would be issued upon conversion.

 

On June 24, 2020, the Company filed with the Secretary of State of the State of Nevada (the “Secretary of State”) a certificate of designation (the “Certificate of Designation”) of Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”). The Certificate of Designation was effective upon filing with the Secretary of State and designated a new series of preferred stock of the Company as Series B Convertible Preferred Stock with 4,000,000 shares authorized for issuance.

 

Upon the occurrence of the events as set forth in paragraph (a) or (b) below, each share of Series B Preferred Stock shall be converted into four (the “Conversion Ratio”) fully paid and non-assessable shares of common stock or any shares of capital stock or other securities of the Company into which such common stock shall hereafter be changed or reclassified (the “Conversion Shares”) as set forth in the Certificate of Designation.

 

(a)       Automatic Conversion

 

Immediately upon the listing of the common stock for trading on the New York Stock Exchange or the Nasdaq Stock Market, all of the issued and outstanding shares of Series B Preferred Stock shall automatically be converted into Conversion Shares without any further action of any holder of Series B Preferred Stock (each, a “Series B Holder” and collectively, “Series B Holders”).

 

(b)       Optional Conversion

 

A Series B Holder shall have the right at any time during the period beginning on the date which is six months following the date that the Series B Preferred Stock is initially issued and prior to any automatic conversion as provided in the Certificate of Designation, to convert all or any part of the outstanding Series B Preferred Stock held by such Series B Holder into Conversion Shares at the Conversion Ratio as provided in the Certificate of Designation, subject to limitations set forth in the Certificate of Designation.

 

Dividends

 

Series B Holders will be entitled to receive a quarterly dividend, until the conversion of the Series B Preferred Stock, at the rate of 8% per annum (the “Series B Dividend”). The Series B Dividend will be cumulative, shall accrue quarterly, and be paid via the issuance of a number of shares of common stock of the Company equal to (1) the dollar amount of the Series B Dividend being paid, divided by (2) $0.25 (the “Stock Dividend”). The Stock Dividend shall be paid via the issuance to the applicable Series B Holder of the applicable shares of common stock via book entry in the books and records of the Company. At March 31, 2022, cumulative unpaid dividends on the Series B Preferred Stock amounted to $361,712. No common stock has been issued as of March 31, 2022 in satisfaction of the preferred stock dividend.

 

Voting Rights

 

Each share of Series B Preferred Stock shall have a number of votes on any matter submitted to the holders of the Company’s common stock, or any class thereof, for a vote, equal to the number of Conversion Shares into which the Series B Preferred Stock is then convertible, and shall vote together with the common stock, or any class thereof, as applicable, as one class on such matter for as long as the share of Series B Preferred Stock is issued and outstanding.

 
10 
 

 

Note 7 – Related Party Transactions

 

Pursuant to an agreement dated June 2013 and amended in July 2021, TBG Holdings Corp. (“TBG”), was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. TBG is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and director, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer and director, and a significant stockholder of the Company. Effective on June 14, 2022, Neil Swartz voluntarily resigned as CEO at MediXall Group, Inc. and the Company appointed Noel J. Guillama-Alvarez as his successor. Under this agreement, we pay TBG a monthly fee of $40,000. In April 2021, we entered into an additional agreement with TBG to provide management services specifically to our Health Karma subsidiary. Under this new agreement, we pay TBG an additional monthly fee of $40,000. During the three months ended March 31, 2022 and 2021, the Company expensed $240,000 and $120,000, respectively, of related party management fees related to these agreements. At March 31, 2022 and December 31, 2021, the Company had prepaid management fees related to the aforementioned agreement with TBG amounting to $116,413 and $276,043, respectively.

 

During the three month period ended March 31, 2021, the Company paid $94,000 in marketing and consulting expenses to two companies which are owned by the former president of Turnkey a related party. There was no such fee during the three month period ended March 31, 2022.

 

R3 Accounting LLC (“R3”), owned by Mr. Hart, provides accounting, tax and bookkeeping services to the Company. During the three months ended March 31, 2022 and 2021, the Company expensed $120,000 and $70,038, respectively, related to R3 services.

 

The Company received short term cash advances during 2021 from Turnkey. The advances are due on demand, unsecured, and do not bear any interest.

 

Prepaid expenses (accounts payable and accrued expenses) to related parties are as follows:

 

        
Related Party 

At

March 31,

2022

  

At

December 31,

2021

 
TBG  $116,413   $276,043 
Turnkey   (549,150)   (549,150)
R3   (40,052)   (18,052)
   $(472,789)  $(291,159)

  

Note 8 – Senior Convertible Debentures and Warrants

 

In March 2022, the Company entered into a securities purchase agreement in which the Company maximum offering amount is $5,000,000. For every $1,000 invested in the offering, the Investors will receive a Debenture with a face amount of $1,000 and Warrants to purchase 350 Common Shares at an exercise price of $1.50 per share expiring on April 30, 2027. Pursuant to this agreement, the Company has entered into three convertible debentures totaling $450,000 with an interest rate of 8% maturing on September 30, 2023. The outstanding debentures are convertible into shares of common stock at $2.00 per share. The debentures may be converted at any time after the issuance date until the debentures are paid off.

 

The Company issued warrants to acquire up to an aggregate 157,500 shares of the Company’s common stock at an exercise price of $1.50 per share. Each Warrant is exercisable by the Investor beginning on the effective date through the fifth-year anniversary thereof.

 

The fair value of each warrant issued during the three months ended March 31, 2022 was estimated on the date of issuance using the Black-Scholes option-pricing model with the following assumptions:

 

     
Stock price  $0.40 
Exercise price  $1.50 
Risk-free interest rate   2.10%
Expected dividend yield   —%
Expected stock volatility   81.03%
Expected life in years   5.00 

 

The expected life was based on the average life of the warrants. Expected volatility is based on historical volatility of Company's common stock. The risk-free rate for periods within the contractual life of the warrants is based on the U.S. Treasury yield curve in effect at the time of issuance. The dividend yield assumption is based on the Company's expectation of dividend payments.

 

The result was a fair value of $0.16 per warrant or $25,129 in aggregate. This fair value was reduced with the relative fair value to $23,800. During the three-month ended March 31, 2022, the Company amortized $680, of the debt discount to interest expense.

 

 

11 
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue” negatives thereof or similar expressions. Forward-looking statements contained in this report speak only as of the date of this report, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, matters associated with:

 

  · our ability to continue as a going concern,
  · our history of losses which we expect to continue,
  · the significant amount of liabilities due to related parties,
  · our ability to raise sufficient capital to fund our company,
  · our ability to integrate acquisitions and the operations of acquired companies,
  · the limited experience of our management in the operations of a public company,
  · potential weaknesses in our internal control over financial reporting,
  · increased costs associated with reporting obligations as a public company,
  · a limited market for our common stock and limitations resulting from our common stock being designated as a penny stock,
  · the ability of our board of directors to issue preferred stock without the consent of our stockholders,
  · our management controls the voting of our outstanding securities,
  · the conversion of shares of Series A and B preferred stock will be very dilutive to our existing common stockholders,
  · risks associated with and unique to health care,
  · risks associated with stability of the internet, data security, exposure to data breach, and
  · risks associated with COVID-19

 

You should read thoroughly this report and the documents that we refer to herein with the understanding that our actual future results may be materially different from and/or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements, including those made in this report, in Part I. Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. Other sections of this report include additional factors which could adversely impact our business and financial performance. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. These forward-looking statements speak only as of the date of this report, and you should not rely on these statements without also considering the risks and uncertainties associated with these statements and our business.

 

12 
 

OTHER PERTINENT INFORMATION

 

Unless specifically set forth to the contrary, when used in this report the terms “MediXall Group”, the “Company,” “we”, “us”, “our” and similar terms refer to MediXall Group, Inc., a Nevada corporation, and its wholly-owned subsidiaries.

 

GENERAL

 

The following Management’s Discussion and Analysis (“MD&A”) is intended to help the reader understand the Company’s results of operations and financial condition. The MD&A is provided as a supplement to, and should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in this Quarterly Report on Form 10-Q.

 

The MD&A is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

OVERVIEW

 

MediXall Group, Inc. (OTCQB:MDXL) is an innovation-driven technology company purposefully designed and structured around delivering products and services to help consumers learn, decide, and pay for healthcare in ways that complement relationships with trusted doctors. The mission of MediXall Group is to revolutionize the medical industry--improve communication, provide better technology and support services, and provide more efficient, cost-effective healthcare for the consumer.

 

 Going Concern

 

We have incurred net losses of approximately $28.2 million since inception through March 31, 2022. The report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2021 contains an explanatory paragraph regarding our ability to continue as a going concern based upon the fact that we are dependent upon our ability to increase revenues along with raising additional external capital as needed. These factors, among others, raise substantial doubt about our ability to continue as a going concern. Our condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. There are no assurances we will be successful in our efforts to generate revenues or report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our company.

 

Results of Operations

 

Three Month Period Ended March 31, 2022 Compared to the Three Month Period Ended March 31, 2021

 

Revenue

 

We had nominal revenue for the three months ended March 31, 2022 and 2021.

 

13 
 

 

Operating Expenses

 

A summary of our operating expense for the three month periods ended March 31, 2022 and 2021 follows:

 

   Three Months Ended     
   March 31,   (Decrease) / 
   2022   2021   Increase 
Operating expense               
Professional fees  $328,657   $339,580    (10,923)
Professional fees – related party   120,000    164,038    (44,038)
Management fee – related party   240,000    120,000    120,000 
Personnel related expenses   1,529,954    601,550    928,404 
Other selling, general, and administrative   199,398    110,404    88,994 
Total operating expense  $2,418,009   $1,335,572   $1,082,437 
                

 

Operating expenses increased $1,082,437, or 81%, to $2,418,009 during the three months ended March 31, 2022 compared to $1,335,572 during the same period in 2021. The increase in total operating expenses is primarily due to:

 

1. The decrease in professional fees of $10,923 primarily resulted from the Company issuing shares of its restricted common stock for consulting services during the three month period ended March 31, 2021. There were no such share issuances during the three month period ended March 31, 2022.

 

2. The decrease in Professional fees – related party of $44,038 is related to $94,000 in marketing and consulting expenses, during the three month period ended March 31, 2021, to two companies which are owned by the former president of Turnkey a related party. There was no such fee during the three month period ended March 31, 2022. This was offset by increased accounting services provided by R3.

 

3. The increase in management fees - related party of $120,000 is due to an additional contract entered into with TBG to provide management services to our wholly-owned subsidiary, Health Karma, Inc during the three month period ended March 31, 2022. There was no such contract during the three month period ended March 31, 2021.

 

4. The increase in personnel related expenses of $928,404 is due to issuing shares of its restricted common stock for employee services during the three month period ended March 31, 2022. There were no such share issuances during the three month period ended March 31, 2021.

 

5. The increase of $88,994 in other selling, general, and administrative is due to an increase in business development and marketing expenses during the three month period ended March 31, 2022.

 

We expect expenses to increase as we move forward with further enhancing the platform.

 

Liquidity and capital resources

 

Liquidity is the ability of a company to generate sufficient cash to satisfy its needs. At March 31, 2022, we had $103,900 in cash and net working capital deficit of $1,007,314.

 

For the three month period ended March 31, 2022, we raised $1,170,000 from sales of our restricted common stock and issuance of convertible debt, and for the three month period ended March 31, 2021, we raised $1,966,875.

 

Net cash used in operating activities for three month period ended March 31, 2022 was $1,127,838, as compared to $1,296,180 for the three month period ended March 31, 2021. This change primarily results from our increased net loss, offset by fluctuations in accounts payable and accrued expenses, accounts payable and accrued expenses-related party and the issuance of common stock for services rendered.

 

Our primary source of capital to develop and implement our business plan has been from sales of common and preferred stock.

 

14 
 

 

 

Other Contractual Obligations

 

None.

 

Off-Balance Sheet Arrangements

  

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

 

Critical Accounting Policies

 

Use of Estimates

 

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.

 

A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustment is reflected in current operations.

 

Risks and Uncertainties

 

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces risk and uncertainty related to the COVID-19 pandemic.

 

Share Based Payment Arrangements

 

The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company fair values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

 

15 
 

Recoverability of Long-Lived Assets

 

The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the three month periods ended March 31, 2022 and 2021. However, there can be no assurances that future impairment tests will not result in a charge to operations.

 

Rights-to-use Intellectual Property

 

The rights-to-use intellectual property (“Intellectual Property”) is an intangible asset arising from the Company’s right to use the proprietary technology and programs of the Virtual Clinic. The Intellectual Property was initially measured at fair value and will be amortized on a straightline basis over its estimated useful life as the economic benefits are consumed or otherwise realized. Management has determined the estimated useful life to be seven years.

 

Website and Development Costs

 

Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of March 31, 2022 and December 31, 2021, the Company has met the capitalization requirements and has incurred $453,084 and $451,404, respectively, in costs related to the development of the MediXall platform. Upon completion, the related assets will be amortized over the estimated useful life of the underlying product. The Company will amortize the cost of the intangible asset using amortization methods that reflect the pattern in which the economic benefits of the intangible asset are consumed or otherwise realized.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

  

We carried out an evaluation as required by paragraph (b) of Rule 13a-15 and 15d-15 of the Exchange Act, under the supervision and with the participation of our management, including our Interim Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March 31, 2022.

  

A material weakness can be defined as an insufficiency of internal controls that may result in a more than remote likelihood that a material misstatement will not be prevented, detected or corrected in a company’s condensed consolidated financial statements.

 

Based upon that evaluation, our Interim Chief Executive Officer and Chief Financial Officer concluded that as of March 31, 2022, our disclosure controls and procedures were not effective, based on the following deficiencies:

  

  · Weaknesses in accounting and finance personnel: We have a small accounting staff and we do not have the robust employee resources and expertise needed to meet complex and intricate GAAP and SEC reporting requirements of a U.S. public company. Additionally, numerous adjustments and proposed adjustments have been noted by our auditors. This is deemed by management to be a material weakness in preparing condensed consolidated financial statements.
     
  · We have written accounting policies and control procedures, but we do not have sufficient staff to implement the related controls. Management had determined that this lack of the implantation of segregation of duties, as required by our written procedures, represents a material weakness in our internal controls.
     
  · Internal control has as its core a basic tenant of segregation of duties. Due to our limited size and economic constraints, the Company is not able to segregate for control purposes various asset control and recording duties and functions to different employees. This lack of segregation of duties had been evaluated by management, and has been deemed to be a material control deficiency.

  

16 
 

The Company has determined that the above internal control weaknesses and deficiencies could result in a reasonable possibility for the condensed consolidated financial statements that a material misstatement will not be prevented or detected on a timely basis by the Company’s internal controls.

  

Management is currently evaluating what steps can be taken in order to address these material weaknesses. As a growing small business, the Company continuously devotes resources to the improvement of our internal control over financial reporting. Due to budget constraints, the staffing size, proficiency and specific expertise in the accounting department is below requirements for the operation. The Company is anticipating correcting deficiencies as funds become available.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes during our last fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 

 

  

17 
 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

The Company has received a Subpoena from the SEC requesting certain documents in connection with an investigation styled, “In the Matter of TBG Holdings Corporation”. This investigation is a non-public, fact-finding inquiry and does not require disclosure by the Company. The Company has decided to disclose this matter in order to more fully keep our shareholders apprised of matters affecting the Company and its shareholders. The investigation in no way has made a conclusion that anyone has violated any securities laws or regulations. Also, this investigation does not mean the SEC has a negative opinion of any person, entity, or security. All SEC investigations are conducted privately.

 

As part of its investigation, the SEC has requested certain financial documents and information related to the Company, as well as documents related to transactions with R3, TBG, Turnkey and other entities.

 

All transactions between the Company and each of R3, TBG and Turnkey are routinely updated and disclosed in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, each as filed with the SEC. These filings can be found on the SEC’s public web site at https://www.sec.gov/cgi-bin/browse-edgar?CIK=1601280&owner=exclude.

 

The Company is cooperating fully with the SEC in its investigation and has supplied, and if requested, will continue to supply, the SEC with all documents requested in a timely fashion.

 

To date, the SEC has informed the Company that it is concluding its investigation and it will not be opening an investigation into the Company and at this time.

 

Various legal claims arise from time to time in the normal course of business which, in the opinion of management, will not have a material effect on the Company's condensed consolidated financial statements.

 

ITEM 1A. RISK FACTORS.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

During the three month period ended March 31, 2022, we:

 

  · Received proceeds of $720,000, net of offering costs of $0, pursuant to a Private Placement Memorandum and for which 1,800,000 shares of restricted common stock were issued. These securities were issued pursuant to exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) thereof.
     

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable to our Company.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

18 
 

ITEM 6. EXHIBITS.

 

Exhibit No.   Description
31.1   Rule 13a-14(a)/ 15d-14(a) Certification of Interim Chief Executive Officer *
31.2   Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer *
32.1   Section 1350 Certification of Interim Chief Executive Officer *
32.2   Section 1350 Certification of Chief Financial Officer *
101.INS   XBRL Instance Document *
101.SCH   XBRL Taxonomy Extension Schema *
101.CAL   XBRL Taxonomy Extension Calculation Linkbase *
101.DEF   XBRL Taxonomy Extension Definition Linkbase *
101.LAB   XBRL Taxonomy Extension Label Linkbase *
101.PRE   XBRL Taxonomy Extension Presentation Linkbase *

———————

* Filed herewith.

 

19 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MediXall Group, Inc.
     
Dated: August 1, 2022 By: /s/ Timothy S. Hart
    Timothy S. Hart
    Chief Financial Officer (Principal Financial and Accounting Officer)
     
     
Dated: August 1, 2022 By: /s/ Noel Guillama-Alvarez
    Noel Guillama-Alvarez
    Interim Chief Executive Officer (Principal Executive Officer)

 

 

 

 

 

 

 20

 

 

 

 

 

 

 

 

 EX-31.1 2 mdxl_ex31z1.htm EXHIBIT 31.1

Exhibit 31.1

 

CERTIFICATIONS

 

I, Noel Guillama-Alvarez, certify that:

 

1.       I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2022 of MediXall Group, Inc.;

 

2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

         

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

         

4.       The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)       Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

         

(b)       Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

         

(c)       Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the year covered by this report based on such evaluation; and

         

(d)       Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.       The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)       All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

         

(b)       Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 Dated: August 1, 2022 /s/ Noel Guillama-Alvarez
  Noel Guillama-Alvarez
 

Interim Chief Executive Officer

(principal executive officer)

 

 EX-31.2 3 mdxl_ex31z2.htm EXHIBIT 31.2

Exhibit 31.2

 

CERTIFICATIONS

 

I, Timothy S. Hart, certify that:

 

1.       I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2022 of MediXall Group, Inc.;

 

2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

         

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

         

4.       The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)       Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

         

(b)       Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

         

(c)       Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the year covered by this report based on such evaluation; and

         

(d)       Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.       The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)       All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

         

(b)       Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 Dated: August 1, 2022 /s/ Timothy S. Hart
  Timothy S. Hart
 

Chief Financial Officer

(principal financial officer)

 

 EX-32.1 4 mdxl_ex32z1.htm EXHIBIT 32.1

Exhibit 32.1

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of MediXall Group, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Noel Guillama-Alvarez, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1)       The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

         

(2)       The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: August 1, 2022 /s/ Noel Guillama-Alvarez
  Noel Guillama-Alvarez
  Interim Chief Executive Officer
  (principal executive officer)

 

 EX-32.2 5 mdxl_ex32z2.htm EXHIBIT 32.2

Exhibit 32.2

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of MediXall Group, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy S. Hart, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1)       The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

         

(2)       The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: August 1, 2022 /s/ Timothy S. Hart
  Timothy S. Hart
  Chief Financial Officer
  (principal financial officer)

 

 EX-101.SCH 6 mdxl-20220331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Nature of Operation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Asset Acquisition link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Right-to-use Intellectual Property link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Senior Convertible Debentures and Warrants link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Right-to-use Intellectual Property (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Senior Convertible Debentures and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Asset Acquisition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Right-to-use Intellectual Property (Schedule of Right-to-use Intellectual Property) (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Right-to-use Intellectual Property (Schedule of amortization expense for right-to-use intellectual property) (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Senior Convertible Debentures and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Senior Convertible Debentures and Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mdxl-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 mdxl-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 mdxl-20220331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Equity Components [Axis] Series A Voting Preferred Stock [Member] Series B Voting Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Legal Entity [Axis] Medi Xall Group Inc [Member] Senior Convertible Debentures and Warrants [Member] Related Party [Axis] T B G [Member] R3 Accounting LLC [Member] T B G Holdings Corp [Member] Turnkey [Member] Long-Term Debt, Type [Axis] Three Convertible Loan Debentures [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS: Cash Prepaid expenses - related party Other assets   Total current assets Furniture and equipment, net Rights-to-use-intellectual property Right-of-use-operating lease asset Website and development costs     Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES: Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Operating lease liability         Total current liabilities Operating lease liability, net of current portion Senior Convertible Debentures, net of discount of $23,800 Total liabilities STOCKHOLDERS' DEFICIT: Preferred Stock, Value, Issued Common Stock, $0.001 par value 750,000,000 shares authorized; 115,901,920 and 110,864,595 shares issued and outstanding Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Net of discount Convertible Preferred stock, par value (in dollars per share) Convertible Preferred stock, shares authorized Convertible Preferred stock, shares issued Convertible Preferred stock, shares outstanding Common Stock, Par value (in dollars per share) Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Income Statement [Abstract] Revenue Operating Expenses     Professional fees     Professional fees - related party     Management fees - related party     Personnel related expenses     Other selling, general and administrative         Total Operating Expenses Loss before income taxes Income taxes Net loss Less preferred stock dividends Net loss to common shareholders Net loss per common share - basic and diluted Weighted average number of common shares outstanding during the periods - basic and diluted Beginning balance, value Beginning balance, Shares Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs, Shares Common stock issued for services Common stock issued for services, Shares Common stock issued in exchange for right-to-use intellectual property Common stock issued in exchange for right-to-use intellectual property, Shares Fair value of Warrants issued with Convertible Debentures Proceeds received from sale of Preferred Stock Proceeds received from sale of Preferred Stock, Shares Net loss Ending balance, value Ending balance, Shares Offering costs Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Common stock issued as compensation for services Amortization of debenture discounts Changes in operating assets and liabilities: Other assets Prepaid expenses - related party Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Amortization of right-of-use operating lease asset Amortization of right-to-use intellectual property Operating lease liability Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Website and development costs Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from the sale of common stock, net of offering costs Proceeds from the sale of preferred stock Proceeds from issuance of convertible debentures Net cash provided by financing activities Net increase in cash Cash at beginning of period Cash at end of period Supplemental Disclosure of Cash Flow Information: Issuance of Common Stock in exchange for of the Right-to-Use Intellectual Property Discount issued with Convertible Debentures Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Nature of Operation Asset Acquisition Asset Acquisition Going Concern Accounting Policies [Abstract] Summary of Significant Accounting Policies Goodwill and Intangible Assets Disclosure [Abstract] Right-to-use Intellectual Property Equity [Abstract] Preferred Stock Related Party Transactions [Abstract] Related Party Transactions Senior Convertible Debentures And Warrants Senior Convertible Debentures and Warrants Basis of Presentation Principles of Consolidation Use of Estimates Subsequent Events Risks and Uncertainties Income Taxes Revenue Recognition Senior Convertible Debentures and Warrants Share-Based Payment Arrangements Loss Per Share Recoverability of Long-Lived Assets Rights-to-use Intellectual Property Website and Development Costs Allowance for Uncollectible Accounts Receivable Recent Accounting Pronouncements Schedule of computation of basic and diluted net loss per share Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share Schedule of Right-to-use Intellectual Property Schedule of amortization expense for right-to-use intellectual property Schedule of prepaid expenses (accounts payable and accrued expenses) to related parties Schedule of assumptions Number of shares issued Intellectual property value Additional shares issued Retained Earnings (Accumulated Deficit) Stock issued Proceeds from issue of stock Basic and Diluted LPS Computation Numerator: Net loss Series B Preferred Stock Dividends Loss available to common stockholders Denominator: Weighted average number of common shares outstanding Basic and diluted LPS Anti-dilutive securities Website and development costs Gross Accumulated amortization Net carrying amount 2022 2023 2024 2025 2026 Thereafter Total Schedule of Stock by Class [Table] Class of Stock [Line Items] Number of common stock issuable for total shares of convertible preferred stock Convertible Preferred stock, par value Dividend rate Stock dividend Cummulative unpaid dividends Common stock issued in satisfaction of preferred stock dividend Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Prepaid expenses- related party Accounts payable and accrued expenses - related party Due from (to) related party Fee for consulting and administrative services Debt Instrument, Periodic Payment Management fee - related party Prepaid expenses- related party Marketing and Consulting expenses Stock price Exercise price Risk-free interest rate Expected dividend yield Expected stock volatility Expected life in years Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Securities purchase agreement, description Convertible loan Interest rate Maturity date Convertible stock per share Issuance of warrants Exercise price [custom:FairValueOfWarrant] [custom:AggregateAmount-0] Fair value reduced amount Amortization of Debt Discount (Premium) Tbg holdings corp member. Represents details pertaining to R3Accounting, LLC. Number of shares issued for total shares of convertible preferred stock that is converted. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses [Default Label] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding AmortizationOfDebentureDiscounts Increase (Decrease) in Other Current Assets IncreaseDecreaseInPrepaidExpensesRelatedParty Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Payable, Related Parties Increase (Decrease) in Operating Liabilities Net Cash Provided by (Used in) Operating Activities WebsiteAndDevelopmentCosts Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents AssetAcquisitionDisclosureTextBlock SeniorConvertibleDebenturesAndWarrantsPolicyTextBlock Net Income (Loss) Available to Common Stockholders, Diluted Capitalized Computer Software, Net Class of Warrant or Right, Exercise Price of Warrants or Rights EX-101.PRE 10 mdxl-20220331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover - shares
 3 Months Ended
Mar. 31, 2022
Aug. 01, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 333-194337  
Entity Registrant Name MediXall Group, Inc.  
Entity Central Index Key 0001601280  
Entity Tax Identification Number 33-0864127  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 2929 East Commercial Blvd.  
Entity Address, Address Line Two PH-D  
Entity Address, City or Town Ft. Lauderdale  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33308  
City Area Code 954  
Local Phone Number 440-4678  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   118,134,789
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
CURRENT ASSETS:    
Cash $ 103,900 $ 63,418
Prepaid expenses - related party 116,413 276,043
Other assets 7,484 3,484
  Total current assets 227,797 342,945
Furniture and equipment, net 20,696 23,376
Rights-to-use-intellectual property 227,571 0
Right-of-use-operating lease asset 295,963 313,856
Website and development costs 453,084 451,404
    Total assets 1,225,111 1,131,581
CURRENT LIABILITIES:    
Accounts payable and accrued expenses 585,720 588,870
Accounts payable and accrued expenses - related party 589,202 567,202
Operating lease liability 60,189 69,258
        Total current liabilities 1,235,111 1,225,330
Operating lease liability, net of current portion 238,615 246,373
Senior Convertible Debentures, net of discount of $23,800 426,880 0
Total liabilities 1,900,606 1,471,703
STOCKHOLDERS' DEFICIT:    
Common Stock, $0.001 par value 750,000,000 shares authorized; 115,901,920 and 110,864,595 shares issued and outstanding 115,901 110,864
Additional paid-in capital 27,396,922 25,327,230
Accumulated deficit (28,192,492) (25,782,390)
Total stockholders' deficit (675,495) (340,122)
Total liabilities and stockholders' deficit 1,225,111 1,131,581
Series A Preferred Stock [Member]    
STOCKHOLDERS' DEFICIT:    
Preferred Stock, Value, Issued 265 265
Series B Preferred Stock [Member]    
STOCKHOLDERS' DEFICIT:    
Preferred Stock, Value, Issued $ 3,909 $ 3,909
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Net of discount $ 23,800  
Common Stock, Par value (in dollars per share) $ 0.001 $ 0.001
Common Stock, shares authorized 750,000,000 750,000,000
Common Stock, shares issued 115,901,920 110,864,595
Common Stock, shares outstanding 115,901,920 110,864,595
Series A Preferred Stock [Member]    
Convertible Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Convertible Preferred stock, shares authorized 1,000,000 1,000,000
Convertible Preferred stock, shares issued 264,894 264,894
Convertible Preferred stock, shares outstanding 264,894 264,894
Series B Preferred Stock [Member]    
Convertible Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Convertible Preferred stock, shares authorized 4,000,000 4,000,000
Convertible Preferred stock, shares issued 3,909,360 3,909,360
Convertible Preferred stock, shares outstanding 3,909,360 3,909,360
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenue $ 7,907 $ 3,271
Operating Expenses    
    Professional fees 328,657 339,580
    Professional fees - related party 120,000 164,038
    Management fees - related party 240,000 120,000
    Personnel related expenses 1,529,954 601,550
    Other selling, general and administrative 199,398 110,404
        Total Operating Expenses 2,418,009 1,335,572
Loss before income taxes (2,410,102) (1,332,301)
Income taxes 0 0
Net loss (2,410,102) (1,332,301)
Less preferred stock dividends 72,840 46,969
Net loss to common shareholders $ (2,482,942) $ (1,379,270)
Net loss per common share - basic and diluted $ (0.02) $ (0.01)
Weighted average number of common shares outstanding during the periods - basic and diluted 114,625,809 100,242,517
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)
Series A Voting Preferred Stock [Member]
Series B Voting Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 265 $ 1,639 $ 98,898 $ 19,862,918 $ (19,581,816) $ 381,904
Beginning balance, Shares at Dec. 31, 2020 264,894 1,639,360 98,898,130      
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs $ 2,488 619,387 621,875
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs, Shares     2,487,550      
Proceeds received from sale of Preferred Stock $ 1,345 1,343,655 1,345,000
Proceeds received from sale of Preferred Stock, Shares   1,345,000        
Net loss (1,332,301) (1,332,301)
Ending balance, value at Mar. 31, 2021 $ 265 $ 2,984 $ 101,386 21,825,960 (20,914,117) 1,016,478
Ending balance, Shares at Mar. 31, 2021 264,894 2,984,360 101,385,680      
Beginning balance, value at Dec. 31, 2021 $ 265 $ 3,909 $ 110,864 25,327,230 (25,782,390) (340,122)
Beginning balance, Shares at Dec. 31, 2021 264,894 3,909,360 110,864,595      
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs $ 1,800 718,200 720,000
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs, Shares     1,800,000      
Common stock issued for services $ 2,737 1,092,192 1,094,929
Common stock issued for services, Shares     2,737,325      
Common stock issued in exchange for right-to-use intellectual property $ 500 235,500 236,000
Common stock issued in exchange for right-to-use intellectual property, Shares     500,000      
Fair value of Warrants issued with Convertible Debentures 23,800 23,800
Net loss (2,410,102) (2,410,102)
Ending balance, value at Mar. 31, 2022 $ 265 $ 3,909 $ 115,901 $ 27,396,922 $ (28,192,492) $ (675,495)
Ending balance, Shares at Mar. 31, 2022 264,894 3,909,360 115,901,920      
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Common Stock [Member]    
Offering costs $ 0 $ 0
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (2,410,102) $ (1,332,301)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 2,680 1,000
Common stock issued as compensation for services 1,094,929 0
Amortization of debenture discounts 680 0
Changes in operating assets and liabilities:    
Other assets (4,000) (45,933)
Prepaid expenses - related party 159,630 0
Accounts payable and accrued expenses (3,150) 82,030
Accounts payable and accrued expenses - related party 22,000 0
Amortization of right-of-use operating lease asset 17,893 18,232
Amortization of right-to-use intellectual property 8,429
Operating lease liability (16,827) (19,208)
Net cash used in operating activities (1,127,838) (1,296,180)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Website and development costs (1,680) 0
Net cash used in investing activities (1,680) 0
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from the sale of common stock, net of offering costs 720,000 621,875
Proceeds from the sale of preferred stock 0 1,345,000
Proceeds from issuance of convertible debentures 450,000 0
Net cash provided by financing activities 1,170,000 1,966,875
Net increase in cash 40,482 670,695
Cash at beginning of period 63,418 645,762
Cash at end of period 103,900 1,316,457
Supplemental Disclosure of Cash Flow Information:    
Issuance of Common Stock in exchange for of the Right-to-Use Intellectual Property 236,000 0
Discount issued with Convertible Debentures $ 23,800 $ 0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Nature of Operation
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Nature of Operation

Note 1 - Organization and Nature of Operation

 

MediXall Group, Inc. (the "Company “or “MediXall”) was incorporated on December 21, 1998 under the laws of the State of Nevada under the name of IP Gate, Inc. The Company had various name changes since, to reflect changes in the Company’s operating strategies.

 

MediXall Group, Inc. (OTCQB:MDXL) is an innovation-driven technology company purposefully designed and structured around delivering products and services to help consumers learn, decide, and pay for healthcare in ways that complement relationships with trusted doctors. The mission of MediXall Group is to revolutionize the medical industry--improve communication, provide better technology and support services, and provide more efficient, cost-effective healthcare for the consumer. The Company generated minimal revenue in 2022 and 2021 as its online healthcare platform is still in the application and development stage. Further discussion on our operations, mission, and initiatives can be found in the Management’s Discussion and Analysis section of this report.

 

The Company has the following wholly-owned subsidiaries: (1) IHL of Florida, Inc., which is dormant, (2) Medixall Financial Group, which is dormant, (3) Medixaid, Inc., and (4) MediXall.com, Inc., which were established to carry out the development and operation of our healthcare marketplace platform, (5) Health Karma, Inc. which was established in 2020 to increase functionality of the MediXall platform.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Asset Acquisition
 3 Months Ended
Mar. 31, 2022
Asset Acquisition  
Asset Acquisition

Note 2 – Asset Acquisition

 

On January 17, 2022, the Company entered into an agreement to acquire the right to use the intellectual property of 24 Hr Virtual Clinic, LLC (“Virtual Clinic”). In connection with the transaction, the Company issued 500,000 shares of common stock of MediXall. In accordance with Accounting Standards Codifiation (“ASC”) 805, the value of the stock issued was measured based on an independent appraisal of the rights to use the intellectual property valued at $236,000, which was determined to be the more clearly determinable measure of fair value.

 

Pursuant to the agreement, the Company has the right to buyout the existing members of the Virtual Clinic for an additional 500,000 shares of MediXall. If this transaction occurs the Virtual Clinic will be renamed to “Wellcare First” and become a wholly-owned subsidiary of the Company.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Going Concern
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

Note 3 – Going Concern

 

The Company had an accumulated deficit of $28,192,492 at March 31, 2022, and does not have sufficient operating cash flows. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.

 

Since the Company has generated minimal revenues from its planned operations, its ability to continue as a going concern is wholly dependent upon its ability to obtain additional financing. Since inception, the Company has funded operations through short-term borrowings, related party loans, and the proceeds from equity sales in order to meet its strategic objectives. The Company's future operations are dependent upon its ability to generate revenues along with additional external funding as needed. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business plan. Subsequent to March 31, 2022, the Company has issued 1,800,000 common shares for total proceeds of $720,000.

 

In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These condensed consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. 

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

 Note 4 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the Securities and Exchange Commission (“SEC”) rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Company’s condensed consolidated financial position as of March 31, 2022 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2022. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on April 19, 2022.

 

Principles of Consolidation

 

These unaudited condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

 

Use of Estimates

 

The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.

 

A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustments are reflected in current operations.

 

Subsequent Events

 

Management has evaluated events occurring subsequent to the unaudited condensed consolidated balance sheet date, through August 1, 2022, which is the date the unaudited condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.

 

Risks and Uncertainties

 

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces significant risk and uncertainty related to the coronavirus global pandemic (“COVID-19”) pandemic.

 

Income Taxes

 

The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification 740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the year that includes the enactment date.

 

Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

 

The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of March 31, 2022. Accordingly, a valuation allowance was recorded against the net deferred tax asset.

 

Revenue Recognition

 

The Company accounts for revenue in accordance with Accounting Standards Updated ("ASU") ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU (collectively, "ASC 606"). The Company had minimal revenues in 2022 and in 2021. The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

 

In 2022 and 2021, the Company generated revenues from selling bundle medical and wellness services to individuals, employer groups, or third-party administrators from the Company’s Health Karma platform. The Company primarily generates revenue from employer customers and consumer subscription fees, which are typically a 12-month commitment in nature. Through our per-Member-per-month (“PMPM”) subscription model, we enter into contracts with our employer customers that pay a fixed monthly rate based on the total number of members. In most cases, members and their dependents have unlimited access to our platform and do not pay extra fees for increased utilization, unless they wish to access services outside the scope of those covered by the subscription.  Our performance obligations are satisfied overtime as we provide access to the Health Karma portal and associated benefits. We recognize revenue monthly as the services are rendered and performance obligations are satisfied.

 

Senior Convertible Debentures and Warrants

 

The senior convertible debentures (Convertible Debt) is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant.

 

Warrants issued with the Convertible Debt are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. The warrant was determined to not have derivative features, and was recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the Convertible Debt. The warrants relative fair values is recorded as a discount to the Convertible Debt and as additional paid-in-capital. Discount on the Convertible Debt is amortized to interest expense over the life of the debt.

 

Share-Based Payment Arrangements

 

The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

 

Loss Per Share

 

The computation of basic loss per share (“LPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive due to net loss for the periods.

 

Following is the computation of basic and diluted loss per share for the three month periods ended March 31, 2022 and 2021:

 

          
   Three Months Ended 
   March 31, 
   2022   2021 
Basic and Diluted LPS Computation          
Numerator:          
Net loss  $(2,410,102)  $(1,332,301)
Series B Preferred Stock Dividends   72,840    46,969 
           
Loss available to common stockholders  $(2,482,942)  $(1,379,270)
           
Denominator:          
Weighted average number of common shares outstanding  $(0.02)  $(0.01)
           
Basic and diluted LPS   114,625,809    100,242,517 

 

Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

 

          
Series A Preferred stock (convertible)   24,900,000    24,900,000 
Series B Preferred stock (convertible)   15,637,440    11,937,440 
Senior Convertible Debentures and Warrants   382,500    —   

 

Recoverability of Long-Lived Assets

 

The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the three periods ended March 31, 2022 and 2021. However, there can be no assurances that future impairment tests will not result in a charge to operations.

  

Rights-to-use Intellectual Property

 

The rights-to-use intellectual property (“Intellectual Property”) is an intangible asset arising from the Company’s right to use the proprietary technology and programs of the Virtual Clinic. The Intellectual Property was initially measured at fair value and will be amortized on a straightline basis over its estimated useful life as the economic benefits are consumed or otherwise realized. Management has determined the estimated useful life to be seven years.

 

Website and Development Costs

 

Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of March 31, 2022 and December 31, 2021, the Company has met the capitalization requirements and has incurred $453,084 and $451,404, respectively, in costs related to the development of the MediXall platform. Upon completion, the related assets will be amortized over the estimated useful life of the underlying product. The Company will amortize the cost of the intangible asset using amortization methods that reflect the pattern in which the economic benefits of the intangible asset are consumed or otherwise realized.

 

Allowance for Uncollectible Accounts Receivable

 

An allowance for uncollectible accounts receivable is recorded when management believes the uncollectability of the accounts receivable is confirmed. Subsequent recoveries, if any, are credited to the allowance. The allowance is determined based on management’s review of the debtor’s ability to repay and repayment history, aging history, and estimated value of collateral, if any.

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Right-to-use Intellectual Property
 3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Right-to-use Intellectual Property

NOTE 5 - Right-to-use Intellectual Property

 

Right-to-use Intellectual Property consists of the following:

 

     
Balances, March 31, 2022     
Gross  $ 236,000 
Accumulated amortization   (8,429)
Net carrying amount  $227,571 

 

Estimated amortization expense for the right-to-use intellectual property for each of the future years ending December 31, is as follows:

 

      
2022 (nine months)   $25,286 
2023    33,714 
2024    33,714 
2025    33,714 
2026    33,714 
Thereafter    67,429 
Total   $227,571 

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Preferred Stock
 3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Preferred Stock

Note 6 – Preferred Stock

 

The 264,894 outstanding Series A preferred shares are convertible into 24,900,000 common shares. The preferred shares do not pay dividends. The number of votes for the preferred shares shall be the same as the amount of shares of common shares that would be issued upon conversion.

 

On June 24, 2020, the Company filed with the Secretary of State of the State of Nevada (the “Secretary of State”) a certificate of designation (the “Certificate of Designation”) of Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”). The Certificate of Designation was effective upon filing with the Secretary of State and designated a new series of preferred stock of the Company as Series B Convertible Preferred Stock with 4,000,000 shares authorized for issuance.

 

Upon the occurrence of the events as set forth in paragraph (a) or (b) below, each share of Series B Preferred Stock shall be converted into four (the “Conversion Ratio”) fully paid and non-assessable shares of common stock or any shares of capital stock or other securities of the Company into which such common stock shall hereafter be changed or reclassified (the “Conversion Shares”) as set forth in the Certificate of Designation.

 

(a)       Automatic Conversion

 

Immediately upon the listing of the common stock for trading on the New York Stock Exchange or the Nasdaq Stock Market, all of the issued and outstanding shares of Series B Preferred Stock shall automatically be converted into Conversion Shares without any further action of any holder of Series B Preferred Stock (each, a “Series B Holder” and collectively, “Series B Holders”).

 

(b)       Optional Conversion

 

A Series B Holder shall have the right at any time during the period beginning on the date which is six months following the date that the Series B Preferred Stock is initially issued and prior to any automatic conversion as provided in the Certificate of Designation, to convert all or any part of the outstanding Series B Preferred Stock held by such Series B Holder into Conversion Shares at the Conversion Ratio as provided in the Certificate of Designation, subject to limitations set forth in the Certificate of Designation.

 

Dividends

 

Series B Holders will be entitled to receive a quarterly dividend, until the conversion of the Series B Preferred Stock, at the rate of 8% per annum (the “Series B Dividend”). The Series B Dividend will be cumulative, shall accrue quarterly, and be paid via the issuance of a number of shares of common stock of the Company equal to (1) the dollar amount of the Series B Dividend being paid, divided by (2) $0.25 (the “Stock Dividend”). The Stock Dividend shall be paid via the issuance to the applicable Series B Holder of the applicable shares of common stock via book entry in the books and records of the Company. At March 31, 2022, cumulative unpaid dividends on the Series B Preferred Stock amounted to $361,712. No common stock has been issued as of March 31, 2022 in satisfaction of the preferred stock dividend.

 

Voting Rights

 

Each share of Series B Preferred Stock shall have a number of votes on any matter submitted to the holders of the Company’s common stock, or any class thereof, for a vote, equal to the number of Conversion Shares into which the Series B Preferred Stock is then convertible, and shall vote together with the common stock, or any class thereof, as applicable, as one class on such matter for as long as the share of Series B Preferred Stock is issued and outstanding.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions
 3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

Note 7 – Related Party Transactions

 

Pursuant to an agreement dated June 2013 and amended in July 2021, TBG Holdings Corp. (“TBG”), was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. TBG is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and director, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer and director, and a significant stockholder of the Company. Effective on June 14, 2022, Neil Swartz voluntarily resigned as CEO at MediXall Group, Inc. and the Company appointed Noel J. Guillama-Alvarez as his successor. Under this agreement, we pay TBG a monthly fee of $40,000. In April 2021, we entered into an additional agreement with TBG to provide management services specifically to our Health Karma subsidiary. Under this new agreement, we pay TBG an additional monthly fee of $40,000. During the three months ended March 31, 2022 and 2021, the Company expensed $240,000 and $120,000, respectively, of related party management fees related to these agreements. At March 31, 2022 and December 31, 2021, the Company had prepaid management fees related to the aforementioned agreement with TBG amounting to $116,413 and $276,043, respectively.

 

During the three month period ended March 31, 2021, the Company paid $94,000 in marketing and consulting expenses to two companies which are owned by the former president of Turnkey a related party. There was no such fee during the three month period ended March 31, 2022.

 

R3 Accounting LLC (“R3”), owned by Mr. Hart, provides accounting, tax and bookkeeping services to the Company. During the three months ended March 31, 2022 and 2021, the Company expensed $120,000 and $70,038, respectively, related to R3 services.

 

The Company received short term cash advances during 2021 from Turnkey. The advances are due on demand, unsecured, and do not bear any interest.

 

Prepaid expenses (accounts payable and accrued expenses) to related parties are as follows:

 

        
Related Party 

At

March 31,

2022

  

At

December 31,

2021

 
TBG  $116,413   $276,043 
Turnkey   (549,150)   (549,150)
R3   (40,052)   (18,052)
   $(472,789)  $(291,159)

  
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Senior Convertible Debentures and Warrants
 3 Months Ended
Mar. 31, 2022
Senior Convertible Debentures And Warrants  
Senior Convertible Debentures and Warrants

Note 8 – Senior Convertible Debentures and Warrants

 

In March 2022, the Company entered into a securities purchase agreement in which the Company maximum offering amount is $5,000,000. For every $1,000 invested in the offering, the Investors will receive a Debenture with a face amount of $1,000 and Warrants to purchase 350 Common Shares at an exercise price of $1.50 per share expiring on April 30, 2027. Pursuant to this agreement, the Company has entered into three convertible debentures totaling $450,000 with an interest rate of 8% maturing on September 30, 2023. The outstanding debentures are convertible into shares of common stock at $2.00 per share. The debentures may be converted at any time after the issuance date until the debentures are paid off.

 

The Company issued warrants to acquire up to an aggregate 157,500 shares of the Company’s common stock at an exercise price of $1.50 per share. Each Warrant is exercisable by the Investor beginning on the effective date through the fifth-year anniversary thereof.

 

The fair value of each warrant issued during the three months ended March 31, 2022 was estimated on the date of issuance using the Black-Scholes option-pricing model with the following assumptions:

 

     
Stock price  $0.40 
Exercise price  $1.50 
Risk-free interest rate   2.10%
Expected dividend yield   —%
Expected stock volatility   81.03%
Expected life in years   5.00 

 

The expected life was based on the average life of the warrants. Expected volatility is based on historical volatility of Company's common stock. The risk-free rate for periods within the contractual life of the warrants is based on the U.S. Treasury yield curve in effect at the time of issuance. The dividend yield assumption is based on the Company's expectation of dividend payments.

 

The result was a fair value of $0.16 per warrant or $25,129 in aggregate. This fair value was reduced with the relative fair value to $23,800. During the three-month ended March 31, 2022, the Company amortized $680, of the debt discount to interest expense.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the Securities and Exchange Commission (“SEC”) rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Company’s condensed consolidated financial position as of March 31, 2022 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2022. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on April 19, 2022.

 
Principles of Consolidation

Principles of Consolidation

 

These unaudited condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

 
Use of Estimates

Use of Estimates

 

The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.

 

A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustments are reflected in current operations.

 
Subsequent Events

Subsequent Events

 

Management has evaluated events occurring subsequent to the unaudited condensed consolidated balance sheet date, through August 1, 2022, which is the date the unaudited condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.

 
Risks and Uncertainties

Risks and Uncertainties

 

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces significant risk and uncertainty related to the coronavirus global pandemic (“COVID-19”) pandemic.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification 740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the year that includes the enactment date.

 

Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

 

The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of March 31, 2022. Accordingly, a valuation allowance was recorded against the net deferred tax asset.

 
Revenue Recognition

Revenue Recognition

 

The Company accounts for revenue in accordance with Accounting Standards Updated ("ASU") ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU (collectively, "ASC 606"). The Company had minimal revenues in 2022 and in 2021. The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

 

In 2022 and 2021, the Company generated revenues from selling bundle medical and wellness services to individuals, employer groups, or third-party administrators from the Company’s Health Karma platform. The Company primarily generates revenue from employer customers and consumer subscription fees, which are typically a 12-month commitment in nature. Through our per-Member-per-month (“PMPM”) subscription model, we enter into contracts with our employer customers that pay a fixed monthly rate based on the total number of members. In most cases, members and their dependents have unlimited access to our platform and do not pay extra fees for increased utilization, unless they wish to access services outside the scope of those covered by the subscription.  Our performance obligations are satisfied overtime as we provide access to the Health Karma portal and associated benefits. We recognize revenue monthly as the services are rendered and performance obligations are satisfied.

 
Senior Convertible Debentures and Warrants

Senior Convertible Debentures and Warrants

 

The senior convertible debentures (Convertible Debt) is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant.

 

Warrants issued with the Convertible Debt are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. The warrant was determined to not have derivative features, and was recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the Convertible Debt. The warrants relative fair values is recorded as a discount to the Convertible Debt and as additional paid-in-capital. Discount on the Convertible Debt is amortized to interest expense over the life of the debt.

 
Share-Based Payment Arrangements

Share-Based Payment Arrangements

 

The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

 
Loss Per Share

Loss Per Share

 

The computation of basic loss per share (“LPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive due to net loss for the periods.

 

Following is the computation of basic and diluted loss per share for the three month periods ended March 31, 2022 and 2021:

 

          
   Three Months Ended 
   March 31, 
   2022   2021 
Basic and Diluted LPS Computation          
Numerator:          
Net loss  $(2,410,102)  $(1,332,301)
Series B Preferred Stock Dividends   72,840    46,969 
           
Loss available to common stockholders  $(2,482,942)  $(1,379,270)
           
Denominator:          
Weighted average number of common shares outstanding  $(0.02)  $(0.01)
           
Basic and diluted LPS   114,625,809    100,242,517 

 

Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

 

          
Series A Preferred stock (convertible)   24,900,000    24,900,000 
Series B Preferred stock (convertible)   15,637,440    11,937,440 
Senior Convertible Debentures and Warrants   382,500    —   

 
Recoverability of Long-Lived Assets

Recoverability of Long-Lived Assets

 

The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the three periods ended March 31, 2022 and 2021. However, there can be no assurances that future impairment tests will not result in a charge to operations.

  
Rights-to-use Intellectual Property

Rights-to-use Intellectual Property

 

The rights-to-use intellectual property (“Intellectual Property”) is an intangible asset arising from the Company’s right to use the proprietary technology and programs of the Virtual Clinic. The Intellectual Property was initially measured at fair value and will be amortized on a straightline basis over its estimated useful life as the economic benefits are consumed or otherwise realized. Management has determined the estimated useful life to be seven years.

 
Website and Development Costs

Website and Development Costs

 

Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of March 31, 2022 and December 31, 2021, the Company has met the capitalization requirements and has incurred $453,084 and $451,404, respectively, in costs related to the development of the MediXall platform. Upon completion, the related assets will be amortized over the estimated useful life of the underlying product. The Company will amortize the cost of the intangible asset using amortization methods that reflect the pattern in which the economic benefits of the intangible asset are consumed or otherwise realized.

 
Allowance for Uncollectible Accounts Receivable

Allowance for Uncollectible Accounts Receivable

 

An allowance for uncollectible accounts receivable is recorded when management believes the uncollectability of the accounts receivable is confirmed. Subsequent recoveries, if any, are credited to the allowance. The allowance is determined based on management’s review of the debtor’s ability to repay and repayment history, aging history, and estimated value of collateral, if any.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Schedule of computation of basic and diluted net loss per share
          
   Three Months Ended 
   March 31, 
   2022   2021 
Basic and Diluted LPS Computation          
Numerator:          
Net loss  $(2,410,102)  $(1,332,301)
Series B Preferred Stock Dividends   72,840    46,969 
           
Loss available to common stockholders  $(2,482,942)  $(1,379,270)
           
Denominator:          
Weighted average number of common shares outstanding  $(0.02)  $(0.01)
           
Basic and diluted LPS   114,625,809    100,242,517 
Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share
          
Series A Preferred stock (convertible)   24,900,000    24,900,000 
Series B Preferred stock (convertible)   15,637,440    11,937,440 
Senior Convertible Debentures and Warrants   382,500    —   
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Right-to-use Intellectual Property (Tables)
 3 Months Ended
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Right-to-use Intellectual Property
     
Balances, March 31, 2022     
Gross  $ 236,000 
Accumulated amortization   (8,429)
Net carrying amount  $227,571 
Schedule of amortization expense for right-to-use intellectual property
      
2022 (nine months)   $25,286 
2023    33,714 
2024    33,714 
2025    33,714 
2026    33,714 
Thereafter    67,429 
Total   $227,571 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions (Tables)
 3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
Schedule of prepaid expenses (accounts payable and accrued expenses) to related parties
        
Related Party 

At

March 31,

2022

  

At

December 31,

2021

 
TBG  $116,413   $276,043 
Turnkey   (549,150)   (549,150)
R3   (40,052)   (18,052)
   $(472,789)  $(291,159)
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Senior Convertible Debentures and Warrants (Tables)
 3 Months Ended
Mar. 31, 2022
Senior Convertible Debentures And Warrants  
Schedule of assumptions
     
Stock price  $0.40 
Exercise price  $1.50 
Risk-free interest rate   2.10%
Expected dividend yield   —%
Expected stock volatility   81.03%
Expected life in years   5.00 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Asset Acquisition (Details Narrative)
 1 Months Ended
Jan. 17, 2022
USD ($)
shares
Intellectual property value | $ $ 236,000
Medi Xall Group Inc [Member]  
Additional shares issued 500,000
Common Stock [Member] | Medi Xall Group Inc [Member]  
Number of shares issued 500,000
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Going Concern (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Retained Earnings (Accumulated Deficit) $ 28,192,492 $ 25,782,390
Common Stock [Member]    
Stock issued 1,800,000  
Proceeds from issue of stock $ 720,000  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Numerator:    
Net loss $ (2,410,102) $ (1,332,301)
Series B Preferred Stock Dividends 72,840 46,969
Loss available to common stockholders $ (2,482,942) $ (1,379,270)
Denominator:    
Weighted average number of common shares outstanding (0.02) (0.01)
Basic and diluted LPS 114,625,809 100,242,517
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details) - shares
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Series A Preferred Stock [Member]    
Anti-dilutive securities 24,900,000 24,900,000
Series B Preferred Stock [Member]    
Anti-dilutive securities 15,637,440 11,937,440
Senior Convertible Debentures and Warrants [Member]    
Anti-dilutive securities 382,500 0
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Details Narrative)
Dec. 31, 2021
USD ($)
Accounting Policies [Abstract]  
Website and development costs $ 453,084
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Right-to-use Intellectual Property (Schedule of Right-to-use Intellectual Property) (Details)
Mar. 31, 2022
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Gross $ 236,000
Accumulated amortization (8,429)
Net carrying amount $ 227,571
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Right-to-use Intellectual Property (Schedule of amortization expense for right-to-use intellectual property) (Details)
Mar. 31, 2022
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2022 $ 25,286
2023 33,714
2024 33,714
2025 33,714
2026 33,714
Thereafter 67,429
Total $ 227,571
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Preferred Stock (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Jun. 24, 2020
Series A Preferred Stock [Member]      
Class of Stock [Line Items]      
Convertible Preferred stock, shares outstanding 264,894 264,894  
Number of common stock issuable for total shares of convertible preferred stock 24,900,000    
Convertible Preferred stock, par value $ 0.001 $ 0.001  
Convertible Preferred stock, shares authorized 1,000,000 1,000,000  
Series B Preferred Stock [Member]      
Class of Stock [Line Items]      
Convertible Preferred stock, shares outstanding 3,909,360 3,909,360  
Convertible Preferred stock, par value $ 0.001 $ 0.001 $ 0.001
Convertible Preferred stock, shares authorized 4,000,000 4,000,000 4,000,000
Dividend rate 8.00%    
Stock dividend $ 0.25    
Cummulative unpaid dividends $ 361,712    
Common stock issued in satisfaction of preferred stock dividend 0    
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]    
Prepaid expenses- related party $ 116,413 $ 276,043
Accounts payable and accrued expenses - related party (589,202) (567,202)
Due from (to) related party (472,789) (291,159)
T B G Holdings Corp [Member]    
Related Party Transaction [Line Items]    
Prepaid expenses- related party 116,413 276,043
Turnkey [Member]    
Related Party Transaction [Line Items]    
Accounts payable and accrued expenses - related party (549,150) (549,150)
R3 Accounting LLC [Member]    
Related Party Transaction [Line Items]    
Accounts payable and accrued expenses - related party $ (40,052) $ (18,052)
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Related Party Transactions (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Apr. 30, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Related Party Transaction [Line Items]        
Debt Instrument, Periodic Payment $ 40,000      
Marketing and Consulting expenses   $ 0 $ 94,000  
T B G [Member]        
Related Party Transaction [Line Items]        
Fee for consulting and administrative services   40,000    
Management fee - related party   240,000 120,000  
Prepaid expenses- related party   116,413   $ 276,043
R3 Accounting LLC [Member]        
Related Party Transaction [Line Items]        
Fee for consulting and administrative services   $ 120,000 $ 70,038  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Senior Convertible Debentures and Warrants (Details)
 3 Months Ended
Mar. 31, 2022
$ / shares
Senior Convertible Debentures And Warrants  
Stock price $ 0.40
Exercise price $ 1.50
Risk-free interest rate 2.10%
Expected dividend yield 0.00%
Expected stock volatility 81.03%
Expected life in years 5 years
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Senior Convertible Debentures and Warrants (Details Narrative)
 1 Months Ended 3 Months Ended
Mar. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Debt Instrument [Line Items]    
Securities purchase agreement, description In March 2022, the Company entered into a securities purchase agreement in which the Company maximum offering amount is $5,000,000. For every $1,000 invested in the offering, the Investors will receive a Debenture with a face amount of $1,000 and Warrants to purchase 350 Common Shares at an exercise price of $1.50 per share expiring on April 30, 2027.  
Convertible stock per share | $ / shares $ 2.00  
Issuance of warrants | shares 157,500 157,500
Exercise price | $ / shares $ 1.50 $ 1.50
[custom:FairValueOfWarrant] | $ / shares   $ 0.16
[custom:AggregateAmount-0] $ 25,129 $ 25,129
Fair value reduced amount 23,800 23,800
Amortization of Debt Discount (Premium)   680
Three Convertible Loan Debentures [Member]    
Debt Instrument [Line Items]    
Convertible loan $ 450,000 $ 450,000
Interest rate 8.00% 8.00%
Maturity date Sep. 30, 2023  
XML 43 mdxl_10q-033122_htm.xml IDEA: XBRL DOCUMENT 0001601280 2022-01-01 2022-03-31 0001601280 2022-08-01 0001601280 2022-03-31 0001601280 2021-12-31 0001601280 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001601280 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001601280 us-gaap:SeriesBPreferredStockMember 2022-03-31 0001601280 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001601280 2021-01-01 2021-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2020-12-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2020-12-31 0001601280 us-gaap:CommonStockMember 2020-12-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001601280 us-gaap:RetainedEarningsMember 2020-12-31 0001601280 2020-12-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-12-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-12-31 0001601280 us-gaap:CommonStockMember 2021-12-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001601280 us-gaap:RetainedEarningsMember 2021-12-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-01-01 2021-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-01-01 2021-03-31 0001601280 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001601280 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2022-01-01 2022-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2022-01-01 2022-03-31 0001601280 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001601280 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-03-31 0001601280 us-gaap:CommonStockMember 2021-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001601280 us-gaap:RetainedEarningsMember 2021-03-31 0001601280 2021-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2022-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2022-03-31 0001601280 us-gaap:CommonStockMember 2022-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001601280 us-gaap:RetainedEarningsMember 2022-03-31 0001601280 us-gaap:CommonStockMember mdxl:MediXallGroupIncMember 2022-01-01 2022-01-17 0001601280 2022-01-17 0001601280 mdxl:MediXallGroupIncMember 2022-01-01 2022-01-17 0001601280 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001601280 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-03-31 0001601280 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001601280 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0001601280 mdxl:SeniorConvertibleDebenturesAndWarrantsMember 2022-01-01 2022-03-31 0001601280 mdxl:SeniorConvertibleDebenturesAndWarrantsMember 2021-01-01 2021-03-31 0001601280 us-gaap:SeriesBPreferredStockMember 2020-06-24 0001601280 mdxl:TBGMember 2022-01-01 2022-03-31 0001601280 2021-04-01 2021-04-30 0001601280 mdxl:TBGMember 2021-01-01 2021-03-31 0001601280 mdxl:TBGMember 2022-03-31 0001601280 mdxl:TBGMember 2021-12-31 0001601280 mdxl:R3AccountingLLCMember 2022-01-01 2022-03-31 0001601280 mdxl:R3AccountingLLCMember 2021-01-01 2021-03-31 0001601280 mdxl:TBGHoldingsCorpMember 2022-03-31 0001601280 mdxl:TBGHoldingsCorpMember 2021-12-31 0001601280 mdxl:TurnkeyMember 2022-03-31 0001601280 mdxl:TurnkeyMember 2021-12-31 0001601280 mdxl:R3AccountingLLCMember 2022-03-31 0001601280 mdxl:R3AccountingLLCMember 2021-12-31 0001601280 2022-03-01 2022-03-31 0001601280 mdxl:ThreeConvertibleLoanDebenturesMember 2022-03-31 0001601280 mdxl:ThreeConvertibleLoanDebenturesMember 2022-03-01 2022-03-31 iso4217:USD shares iso4217:USD shares pure 0001601280 false --12-31 2022 Q1 10-Q true 2022-03-31 false 333-194337 MediXall Group, Inc. NV 33-0864127 2929 East Commercial Blvd. PH-D Ft. Lauderdale FL 33308 954 440-4678 Yes Yes Non-accelerated Filer true false false false 118134789 103900 63418 116413 276043 7484 3484 227797 342945 20696 23376 227571 0 295963 313856 453084 451404 1225111 1131581 585720 588870 589202 567202 60189 69258 1235111 1225330 238615 246373 23800 426880 0 1900606 1471703 0.001 0.001 1000000 1000000 264894 264894 264894 264894 265 265 0.001 0.001 4000000 4000000 3909360 3909360 3909360 3909360 3909 3909 0.001 0.001 750000000 750000000 115901920 115901920 110864595 110864595 115901 110864 27396922 25327230 -28192492 -25782390 -675495 -340122 1225111 1131581 7907 3271 328657 339580 120000 164038 240000 120000 1529954 601550 199398 110404 2418009 1335572 -2410102 -1332301 0 0 -2410102 -1332301 72840 46969 -2482942 -1379270 -0.02 -0.01 114625809 100242517 264894 265 1639360 1639 98898130 98898 19862918 -19581816 381904 0 2487550 2488 619387 621875 1345000 1345 1343655 1345000 -1332301 -1332301 264894 265 2984360 2984 101385680 101386 21825960 -20914117 1016478 264894 265 3909360 3909 110864595 110864 25327230 -25782390 -340122 0 1800000 1800 718200 720000 2737325 2737 1092192 1094929 500000 500 235500 236000 23800 23800 -2410102 -2410102 264894 265 3909360 3909 115901920 115901 27396922 -28192492 -675495 -2410102 -1332301 2680 1000 1094929 0 -680 -0 4000 45933 159630 0 -3150 82030 22000 0 17893 18232 8429 -16827 -19208 -1127838 -1296180 1680 -0 -1680 0 720000 621875 0 1345000 450000 0 1170000 1966875 40482 670695 63418 645762 103900 1316457 236000 0 23800 0 <p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zEPeMwLaGlB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 1 - <span id="xdx_82B_zgApFJQdJKp6">Organization and Nature of Operation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">MediXall Group, Inc. (the "Company “or “MediXall”) was incorporated on December 21, 1998 under the laws of the State of Nevada under the name of IP Gate, Inc. The Company had various name changes since, to reflect changes in the Company’s operating strategies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">MediXall Group, Inc. (OTCQB:MDXL) is an innovation-driven technology company purposefully designed and structured around delivering products and services to help consumers learn, decide, and pay for healthcare in ways that complement relationships with trusted doctors. The mission of MediXall Group is to revolutionize the medical industry--improve communication, provide better technology and support services, and provide more efficient, cost-effective healthcare for the consumer. The Company generated minimal revenue in 2022 and 2021 as its online healthcare platform is still in the application and development stage. Further discussion on our operations, mission, and initiatives can be found in the Management’s Discussion and Analysis section of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has the following wholly-owned subsidiaries: (1) IHL of Florida, Inc., which is dormant, (2) Medixall Financial Group, which is dormant, (3) Medixaid, Inc., and (4) MediXall.com, Inc., which were established to carry out the development and operation of our healthcare marketplace platform, (5) Health Karma, Inc. which was established in 2020 to increase functionality of the MediXall platform. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_80A_ecustom--AssetAcquisitionDisclosureTextBlock_zj0yXkGA93kl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 2 – <span id="xdx_820_zJ1MOEyJSLc5">Asset Acquisition</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 17, 2022, the Company entered into an agreement to acquire the right to use the intellectual property of 24 Hr Virtual Clinic, LLC (“Virtual Clinic”). In connection with the transaction, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220117__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--MediXallGroupIncMember_zLxjsmT2HaK8" title="Number of shares issued">500,000</span> shares of common stock of MediXall. In accordance with Accounting Standards Codifiation (“ASC”) 805, the value of the stock issued was measured based on an independent appraisal of the rights to use the intellectual property valued at $<span id="xdx_900_ecustom--IntellectualPropertyValue_iI_c20220117_zNOCzBDTuc38" title="Intellectual property value">236,000</span>, which was determined to be the more clearly determinable measure of fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the agreement, the Company has the right to buyout the existing members of the Virtual Clinic for an additional <span id="xdx_904_ecustom--AdditionalSharesIssued_c20220101__20220117__dei--LegalEntityAxis__custom--MediXallGroupIncMember_zqHICnWviRt4" title="Additional shares issued">500,000</span> shares of MediXall. If this transaction occurs the Virtual Clinic will be renamed to “Wellcare First” and become a wholly-owned subsidiary of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> 500000 236000 500000 <p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z6P0MXczmsZc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 3 – <span id="xdx_82A_z4TGxJLvAxB1">Going Concern</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company had an accumulated deficit of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220331_ztBixKa7uPi7">28,192,492</span> at March 31, 2022, and does not have sufficient operating cash flows. The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since the Company has generated minimal revenues from its planned operations, its ability to continue as a going concern is wholly dependent upon its ability to obtain additional financing. Since inception, the Company has funded operations through short-term borrowings, related party loans, and the proceeds from equity sales in order to meet its strategic objectives. The Company's future operations are dependent upon its ability to generate revenues along with additional external funding as needed. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business plan. Subsequent to March 31, 2022, the Company has issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAj9WiNFfnl" title="Stock issued">1,800,000</span> common shares for total proceeds of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdcrRu9DwrJ7" title="Proceeds from issue of stock">720,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These condensed consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> -28192492 1800000 720000 <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zHCsg2Ri6Cpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <b><span style="text-decoration: underline">Note 4 - <span id="xdx_828_zuaqgavXj5e2">Summary of Significant Accounting Policies</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdloqoCA6Mo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_867_z0FE8nKwJfLi">Basis of Presentation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the Securities and Exchange Commission (“SEC”) rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Company’s condensed consolidated financial position as of March 31, 2022 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2022. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on April 19, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zNduBzvmYnW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_861_z5HGKwIAP1X">Principles of Consolidation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These unaudited condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_846_eus-gaap--UseOfEstimates_z2Oa1XAppvQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86D_zjMsx5q4beJ4">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustments are reflected in current operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z48ygADTZkI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_862_zmZc2A3qSBi3">Subsequent Events</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management has evaluated events occurring subsequent to the unaudited condensed consolidated balance sheet date, through August 1, 2022, which is the date the unaudited condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z6O2ZBMTD9d3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86C_ztdkYldrmEt4">Risks and Uncertainties</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces significant risk and uncertainty related to the coronavirus global pandemic (“COVID-19”) pandemic.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zaeupzCu46V4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86E_zooSFaHOXVpj">Income Taxes</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification 740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the year that includes the enactment date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of March 31, 2022. Accordingly, a valuation allowance was recorded against the net deferred tax asset.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zkTxlzDoPdp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86F_zBvqOAvTdMz7">Revenue Recognition</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for revenue in accordance with Accounting Standards Updated ("ASU") ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU (collectively, "ASC 606"). The Company had minimal revenues in 2022 and in 2021. The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">In 2022 and 2021, the Company generated revenues from selling bundle medical and wellness services to individuals, employer groups, or third-party administrators from the Company’s Health Karma platform. The Company primarily generates revenue from employer customers and consumer subscription fees, which are typically a 12-month commitment in nature. Through our per-Member-per-month (“PMPM”) subscription model, we enter into contracts with our employer customers that pay a fixed monthly rate based on the total number of members. In most cases, members and their dependents have unlimited access to our platform and do not pay extra fees for increased utilization, unless they wish to access services outside the scope of those covered by the subscription.  Our performance obligations are satisfied overtime as we provide access to the Health Karma portal and associated benefits. We recognize revenue monthly as the services are rendered and performance obligations are satisfied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"> </p> <p id="xdx_842_ecustom--SeniorConvertibleDebenturesAndWarrantsPolicyTextBlock_z4VuwpVkuVM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zSuRYlNnaS0i">Senior Convertible Debentures and Warrants</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The senior convertible debentures (Convertible Debt) is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">Warrants issued with the Convertible Debt are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. The warrant was determined to not have derivative features, and was recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the Convertible Debt. The warrants relative fair values is recorded as a discount to the Convertible Debt and as additional paid-in-capital. Discount on the Convertible Debt is amortized to interest expense over the life of the debt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaR33ncEwO08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_866_zo3R2nZSW0U7">Share-Based Payment Arrangements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values the stock-based compensation at the market price for the Company's stock as of the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zoFgUUqtGa23" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86B_zgED8IMF3cDk"><span id="xdx_869_zA9zDg6KdtM3">Loss Per Share</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The computation of basic loss per share (“LPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive due to net loss for the periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is the computation of basic and diluted loss per share for the three month periods ended March 31, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zH214cMLeC51" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B5_zB2u6Ql2UBM3" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220101__20220331_zJrFwfUFZHDf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20210101__20210331_zKgGd3sKoTr9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_ecustom--EarningsPerSharesBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">Basic and Diluted LPS Computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--NumeratorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i02_pp0p0" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; text-align: left">Net loss</td><td style="width: 1%"> </td> <td style="text-align: left">$</td><td style="width: 14%; text-align: right">(2,410,102</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,332,301</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DividendsPreferredStockStock_i02_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series B Preferred Stock Dividends</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">72,840</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,969</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--LossAvailableToCommonStockholders_i02_pp0p0_zSSona4RS4y2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Loss available to common stockholders</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,482,942</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,379,270</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DenominatorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WeightedAverageNumberOfCommonSharesOutstanding_i01_zQpntBONl5Aj" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="padding-bottom: 1pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.02</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.01</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--BasicAndDilutedLps_i01_zTPqmjDuqAQ8" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted LPS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">114,625,809</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">100,242,517</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zHejc0k6IA09" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zf6dTsz2kN4i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8B3_zflT2rFWMpdg" style="display: none">Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt">Series A Preferred stock (convertible)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zip5y0joFjPa" style="width: 14%; font-size: 10pt; text-align: right" title="Anti-dilutive securities">24,900,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z9cKI28KNoV1" style="width: 14%; font-size: 10pt; text-align: right" title="Anti-dilutive securities">24,900,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Series B Preferred stock (convertible)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUkWo9MjyJF4" style="font-size: 10pt; text-align: right" title="Anti-dilutive securities">15,637,440</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUfqH0C9l2h3" style="font-size: 10pt; text-align: right" title="Anti-dilutive securities">11,937,440</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Senior Convertible Debentures and Warrants</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeniorConvertibleDebenturesAndWarrantsMember_zxnsiVOIG9Ug" style="font-size: 10pt; text-align: right">382,500</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20210101__20210331__us-gaap--StatementClassOfStockAxis__custom--SeniorConvertibleDebenturesAndWarrantsMember_z3dNuOK3Bkoe" style="font-size: 10pt; text-align: right">—  </td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zFI5fovori3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i/></p> <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_znMwqTmNxzn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_864_z2DYQlokrI19">Recoverability of Long-Lived Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the three periods ended March 31, 2022 and 2021. However, there can be no assurances that future impairment tests will not result in a charge to operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_84A_ecustom--RightsToUseIntellectualPropertyPolicyTextBlock_zRoCrFgRVDSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span><span id="xdx_86B_z2bAJzVUmRca">Rights-to-use Intellectual Property</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The rights-to-use intellectual property (“Intellectual Property”) is an intangible asset arising from the Company’s right to use the proprietary technology and programs of the Virtual Clinic. The Intellectual Property was initially measured at fair value and will be amortized on a straightline basis over its estimated useful life as the economic benefits are consumed or otherwise realized. Management has determined the estimated useful life to be seven years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_ziclJuYBnKAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_867_zIfeEjgyK5Ue">Website and Development Costs</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of March 31, 2022 and December 31, 2021, the Company has met the capitalization requirements and has incurred $<span id="xdx_901_eus-gaap--CapitalizedComputerSoftwareNet_iI_pp0p0_c20211231_zLQgr0muHIna" title="Website and development costs">453,084 and $451,404, respectively,</span> in costs related to the development of the MediXall platform. Upon completion, the related assets will be amortized over the estimated useful life of the underlying product. The Company will amortize the cost of the intangible asset using amortization methods that reflect the pattern in which the economic benefits of the intangible asset are consumed or otherwise realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p> <p id="xdx_84F_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zApTGk3P2kEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_z8GNbwqMBGL6">Allowance for Uncollectible Accounts Receivable</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An allowance for uncollectible accounts receivable is recorded when management believes the uncollectability of the accounts receivable is confirmed. Subsequent recoveries, if any, are credited to the allowance. The allowance is determined based on management’s review of the debtor’s ability to repay and repayment history, aging history, and estimated value of collateral, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwnk8H2AYTYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86D_z3ONYq110qFl">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zdloqoCA6Mo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_867_z0FE8nKwJfLi">Basis of Presentation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the Securities and Exchange Commission (“SEC”) rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Company’s condensed consolidated financial position as of March 31, 2022 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2022. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on April 19, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zNduBzvmYnW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_861_z5HGKwIAP1X">Principles of Consolidation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These unaudited condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_846_eus-gaap--UseOfEstimates_z2Oa1XAppvQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86D_zjMsx5q4beJ4">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustments are reflected in current operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z48ygADTZkI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_862_zmZc2A3qSBi3">Subsequent Events</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management has evaluated events occurring subsequent to the unaudited condensed consolidated balance sheet date, through August 1, 2022, which is the date the unaudited condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z6O2ZBMTD9d3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86C_ztdkYldrmEt4">Risks and Uncertainties</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces significant risk and uncertainty related to the coronavirus global pandemic (“COVID-19”) pandemic.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zaeupzCu46V4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86E_zooSFaHOXVpj">Income Taxes</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification 740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the year that includes the enactment date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of March 31, 2022. Accordingly, a valuation allowance was recorded against the net deferred tax asset.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_847_eus-gaap--RevenueRecognitionPolicyTextBlock_zkTxlzDoPdp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86F_zBvqOAvTdMz7">Revenue Recognition</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for revenue in accordance with Accounting Standards Updated ("ASU") ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU (collectively, "ASC 606"). The Company had minimal revenues in 2022 and in 2021. The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">In 2022 and 2021, the Company generated revenues from selling bundle medical and wellness services to individuals, employer groups, or third-party administrators from the Company’s Health Karma platform. The Company primarily generates revenue from employer customers and consumer subscription fees, which are typically a 12-month commitment in nature. Through our per-Member-per-month (“PMPM”) subscription model, we enter into contracts with our employer customers that pay a fixed monthly rate based on the total number of members. In most cases, members and their dependents have unlimited access to our platform and do not pay extra fees for increased utilization, unless they wish to access services outside the scope of those covered by the subscription.  Our performance obligations are satisfied overtime as we provide access to the Health Karma portal and associated benefits. We recognize revenue monthly as the services are rendered and performance obligations are satisfied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"> </p> <p id="xdx_842_ecustom--SeniorConvertibleDebenturesAndWarrantsPolicyTextBlock_z4VuwpVkuVM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zSuRYlNnaS0i">Senior Convertible Debentures and Warrants</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The senior convertible debentures (Convertible Debt) is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">Warrants issued with the Convertible Debt are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. The warrant was determined to not have derivative features, and was recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the Convertible Debt. The warrants relative fair values is recorded as a discount to the Convertible Debt and as additional paid-in-capital. Discount on the Convertible Debt is amortized to interest expense over the life of the debt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaR33ncEwO08" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_866_zo3R2nZSW0U7">Share-Based Payment Arrangements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values the stock-based compensation at the market price for the Company's stock as of the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zoFgUUqtGa23" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86B_zgED8IMF3cDk"><span id="xdx_869_zA9zDg6KdtM3">Loss Per Share</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The computation of basic loss per share (“LPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive due to net loss for the periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is the computation of basic and diluted loss per share for the three month periods ended March 31, 2022 and 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zH214cMLeC51" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B5_zB2u6Ql2UBM3" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220101__20220331_zJrFwfUFZHDf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20210101__20210331_zKgGd3sKoTr9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_ecustom--EarningsPerSharesBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">Basic and Diluted LPS Computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--NumeratorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i02_pp0p0" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; text-align: left">Net loss</td><td style="width: 1%"> </td> <td style="text-align: left">$</td><td style="width: 14%; text-align: right">(2,410,102</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,332,301</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DividendsPreferredStockStock_i02_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series B Preferred Stock Dividends</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">72,840</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,969</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--LossAvailableToCommonStockholders_i02_pp0p0_zSSona4RS4y2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Loss available to common stockholders</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,482,942</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,379,270</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DenominatorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WeightedAverageNumberOfCommonSharesOutstanding_i01_zQpntBONl5Aj" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="padding-bottom: 1pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.02</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.01</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--BasicAndDilutedLps_i01_zTPqmjDuqAQ8" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted LPS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">114,625,809</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">100,242,517</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zHejc0k6IA09" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zf6dTsz2kN4i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8B3_zflT2rFWMpdg" style="display: none">Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt">Series A Preferred stock (convertible)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zip5y0joFjPa" style="width: 14%; font-size: 10pt; text-align: right" title="Anti-dilutive securities">24,900,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z9cKI28KNoV1" style="width: 14%; font-size: 10pt; text-align: right" title="Anti-dilutive securities">24,900,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Series B Preferred stock (convertible)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUkWo9MjyJF4" style="font-size: 10pt; text-align: right" title="Anti-dilutive securities">15,637,440</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUfqH0C9l2h3" style="font-size: 10pt; text-align: right" title="Anti-dilutive securities">11,937,440</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Senior Convertible Debentures and Warrants</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeniorConvertibleDebenturesAndWarrantsMember_zxnsiVOIG9Ug" style="font-size: 10pt; text-align: right">382,500</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20210101__20210331__us-gaap--StatementClassOfStockAxis__custom--SeniorConvertibleDebenturesAndWarrantsMember_z3dNuOK3Bkoe" style="font-size: 10pt; text-align: right">—  </td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zFI5fovori3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i/></p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zH214cMLeC51" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B5_zB2u6Ql2UBM3" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20220101__20220331_zJrFwfUFZHDf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20210101__20210331_zKgGd3sKoTr9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_ecustom--EarningsPerSharesBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left">Basic and Diluted LPS Computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--NumeratorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td>Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i02_pp0p0" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; text-align: left">Net loss</td><td style="width: 1%"> </td> <td style="text-align: left">$</td><td style="width: 14%; text-align: right">(2,410,102</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,332,301</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DividendsPreferredStockStock_i02_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Series B Preferred Stock Dividends</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">72,840</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,969</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--LossAvailableToCommonStockholders_i02_pp0p0_zSSona4RS4y2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Loss available to common stockholders</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,482,942</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,379,270</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DenominatorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WeightedAverageNumberOfCommonSharesOutstanding_i01_zQpntBONl5Aj" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="padding-bottom: 1pt">Weighted average number of common shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.02</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.01</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--BasicAndDilutedLps_i01_zTPqmjDuqAQ8" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted LPS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">114,625,809</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">100,242,517</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -2410102 -1332301 72840 46969 -2482942 -1379270 -0.02 -0.01 114625809 100242517 <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zf6dTsz2kN4i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8B3_zflT2rFWMpdg" style="display: none">Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; font-size: 10pt; text-align: left; padding-left: 5.4pt">Series A Preferred stock (convertible)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zip5y0joFjPa" style="width: 14%; font-size: 10pt; text-align: right" title="Anti-dilutive securities">24,900,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z9cKI28KNoV1" style="width: 14%; font-size: 10pt; text-align: right" title="Anti-dilutive securities">24,900,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Series B Preferred stock (convertible)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUkWo9MjyJF4" style="font-size: 10pt; text-align: right" title="Anti-dilutive securities">15,637,440</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUfqH0C9l2h3" style="font-size: 10pt; text-align: right" title="Anti-dilutive securities">11,937,440</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Senior Convertible Debentures and Warrants</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeniorConvertibleDebenturesAndWarrantsMember_zxnsiVOIG9Ug" style="font-size: 10pt; text-align: right">382,500</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20210101__20210331__us-gaap--StatementClassOfStockAxis__custom--SeniorConvertibleDebenturesAndWarrantsMember_z3dNuOK3Bkoe" style="font-size: 10pt; text-align: right">—  </td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> 24900000 24900000 15637440 11937440 382500 0 <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_znMwqTmNxzn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_864_z2DYQlokrI19">Recoverability of Long-Lived Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the three periods ended March 31, 2022 and 2021. However, there can be no assurances that future impairment tests will not result in a charge to operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p id="xdx_84A_ecustom--RightsToUseIntellectualPropertyPolicyTextBlock_zRoCrFgRVDSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span><span id="xdx_86B_z2bAJzVUmRca">Rights-to-use Intellectual Property</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The rights-to-use intellectual property (“Intellectual Property”) is an intangible asset arising from the Company’s right to use the proprietary technology and programs of the Virtual Clinic. The Intellectual Property was initially measured at fair value and will be amortized on a straightline basis over its estimated useful life as the economic benefits are consumed or otherwise realized. Management has determined the estimated useful life to be seven years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_ziclJuYBnKAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_867_zIfeEjgyK5Ue">Website and Development Costs</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of March 31, 2022 and December 31, 2021, the Company has met the capitalization requirements and has incurred $<span id="xdx_901_eus-gaap--CapitalizedComputerSoftwareNet_iI_pp0p0_c20211231_zLQgr0muHIna" title="Website and development costs">453,084 and $451,404, respectively,</span> in costs related to the development of the MediXall platform. Upon completion, the related assets will be amortized over the estimated useful life of the underlying product. The Company will amortize the cost of the intangible asset using amortization methods that reflect the pattern in which the economic benefits of the intangible asset are consumed or otherwise realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p> 453084 <p id="xdx_84F_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zApTGk3P2kEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86F_z8GNbwqMBGL6">Allowance for Uncollectible Accounts Receivable</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An allowance for uncollectible accounts receivable is recorded when management believes the uncollectability of the accounts receivable is confirmed. Subsequent recoveries, if any, are credited to the allowance. The allowance is determined based on management’s review of the debtor’s ability to repay and repayment history, aging history, and estimated value of collateral, if any.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zwnk8H2AYTYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_86D_z3ONYq110qFl">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_80A_eus-gaap--IntangibleAssetsDisclosureTextBlock_z9yVCIyZGcn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">NOTE 5 - <span id="xdx_823_zt8TMetgzyf2">Right-to-use Intellectual Property</span> </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Right-to-use Intellectual Property consists of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfRightToUseIntellectualPropertyTableTextBlock_zv3L5IwxXZB7" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Right-to-use Intellectual Property (Schedule of Right-to-use Intellectual Property) (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt"><span id="xdx_8BF_zbmzEaEPcyf6" style="display: none">Schedule of Right-to-use Intellectual Property </span></span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center; padding-left: 10pt"/><td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"> </span></td><td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"> </span></td><td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-size: 10pt">Balances, March 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 70%; font-size: 10pt">Gross</td><td style="width: 10%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$ </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331_zSU1NR80VyN7" style="width: 18%; font-size: 10pt; text-align: right" title="Gross">236,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated amortization</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331_zF9MxzNmU6Kh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accumulated amortization">(8,429</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net carrying amount</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20220331_zjZ1ex5mGeAg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net carrying amount">227,571</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z0GsgtPEgsy" style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated amortization expense for the right-to-use intellectual property for each of the future years ending December 31, is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfAmortizationExpenseForTheRightToUseIntellectualPropertyTableTextBlock_ze1QhgK3qw6h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Right-to-use Intellectual Property (Schedule of amortization expense for right-to-use intellectual property) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left"><span id="xdx_8B0_z0CfRDgEtByf" style="display: none">Schedule of amortization expense for right-to-use intellectual property</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; width: 78%; text-align: left"><span style="font-size: 10pt">2022 (nine months)</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0_c20220331_zLPYh2MkLqt4" style="width: 18%; text-align: right" title="2022">25,286</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_pp0p0_c20220331_zPaFxnzWhV6a" style="text-align: right" title="2023">33,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_pp0p0_c20220331_zABDw9vJLzv2" style="text-align: right" title="2024">33,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">2025</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_pp0p0_c20220331_zDFDitsgyqge" style="text-align: right" title="2025">33,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_pp0p0_c20220331_zRGhY5xht6pl" style="text-align: right" title="2026">33,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_iI_pp0p0_c20220331_zdul4CbXaWme" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">67,429</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="padding-bottom: 2.5pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20220331_zOuvfd9C8yt1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">227,571</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zzINnfpmrKX" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfRightToUseIntellectualPropertyTableTextBlock_zv3L5IwxXZB7" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Right-to-use Intellectual Property (Schedule of Right-to-use Intellectual Property) (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt"><span id="xdx_8BF_zbmzEaEPcyf6" style="display: none">Schedule of Right-to-use Intellectual Property </span></span></td> <td style="vertical-align: bottom; font-size: 10pt; text-align: center; padding-left: 10pt"/><td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt"> </span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"> </span></td><td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"> </span></td><td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-size: 10pt">Balances, March 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 70%; font-size: 10pt">Gross</td><td style="width: 10%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$ </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331_zSU1NR80VyN7" style="width: 18%; font-size: 10pt; text-align: right" title="Gross">236,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated amortization</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331_zF9MxzNmU6Kh" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accumulated amortization">(8,429</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net carrying amount</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20220331_zjZ1ex5mGeAg" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Net carrying amount">227,571</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 236000 -8429 227571 <table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfAmortizationExpenseForTheRightToUseIntellectualPropertyTableTextBlock_ze1QhgK3qw6h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Right-to-use Intellectual Property (Schedule of amortization expense for right-to-use intellectual property) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left"><span id="xdx_8B0_z0CfRDgEtByf" style="display: none">Schedule of amortization expense for right-to-use intellectual property</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; width: 78%; text-align: left"><span style="font-size: 10pt">2022 (nine months)</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_iI_pp0p0_c20220331_zLPYh2MkLqt4" style="width: 18%; text-align: right" title="2022">25,286</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">2023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_iI_pp0p0_c20220331_zPaFxnzWhV6a" style="text-align: right" title="2023">33,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">2024</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_iI_pp0p0_c20220331_zABDw9vJLzv2" style="text-align: right" title="2024">33,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: left">2025</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_iI_pp0p0_c20220331_zDFDitsgyqge" style="text-align: right" title="2025">33,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="vertical-align: top; text-align: left">2026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_iI_pp0p0_c20220331_zRGhY5xht6pl" style="text-align: right" title="2026">33,714</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_iI_pp0p0_c20220331_zdul4CbXaWme" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter">67,429</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="padding-bottom: 2.5pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20220331_zOuvfd9C8yt1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">227,571</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 25286 33714 33714 33714 33714 67429 227571 <p id="xdx_808_eus-gaap--PreferredStockTextBlock_zYCBRYeP3GEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 6 – <span id="xdx_824_zYiK4og7FQr2">Preferred Stock</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The <span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5SQETk7mmg5" title="Convertible Preferred stock, shares outstanding">264,894</span> outstanding Series A preferred shares are convertible into <span id="xdx_906_ecustom--ConvertiblePreferredStockTotalSharesIssuedUponConversion_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zNorgPGAwSH9" title="Number of common stock issuable for total shares of convertible preferred stock">24,900,000</span> common shares. The preferred shares do not pay dividends. The number of votes for the preferred shares shall be the same as the amount of shares of common shares that would be issued upon conversion.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 24, 2020, the Company filed with the Secretary of State of the State of Nevada (the “Secretary of State”) a certificate of designation (the “Certificate of Designation”) of <i>Series B Convertible Preferred Stock</i>, par value $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20200624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Convertible Preferred stock, par value">0.001</span> per share (the “Series B Preferred Stock”). The Certificate of Designation was effective upon filing with the Secretary of State and designated a new series of preferred stock of the Company as Series B Convertible Preferred Stock with <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_c20200624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Convertible Preferred stock, shares authorized">4,000,000</span> shares authorized for issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon the occurrence of the events as set forth in paragraph (a) or (b) below, each share of Series B Preferred Stock shall be converted into four (the “Conversion Ratio”) fully paid and non-assessable shares of common stock or any shares of capital stock or other securities of the Company into which such common stock shall hereafter be changed or reclassified (the “Conversion Shares”) as set forth in the Certificate of Designation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>(a)       <span style="text-decoration: underline">Automatic Conversion</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Immediately upon the listing of the common stock for trading on the New York Stock Exchange or the Nasdaq Stock Market, all of the issued and outstanding shares of Series B Preferred Stock shall automatically be converted into Conversion Shares without any further action of any holder of Series B Preferred Stock (each, a “Series B Holder” and collectively, “Series B Holders”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>(b)       <span style="text-decoration: underline">Optional Conversion</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A Series B Holder shall have the right at any time during the period beginning on the date which is six months following the date that the Series B Preferred Stock is initially issued and prior to any automatic conversion as provided in the Certificate of Designation, to convert all or any part of the outstanding Series B Preferred Stock held by such Series B Holder into Conversion Shares at the Conversion Ratio as provided in the Certificate of Designation, subject to limitations set forth in the Certificate of Designation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><i><span style="text-decoration: underline">Dividends</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Series B Holders will be entitled to receive a quarterly dividend, until the conversion of the Series B Preferred Stock, at the rate of <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_dp_c20220101__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqIjiGdOV4C8" title="Dividend rate">8</span>% per annum (the “Series B Dividend”). The Series B Dividend will be cumulative, shall accrue quarterly, and be paid via the issuance of a number of shares of common stock of the Company equal to (1) the dollar amount of the Series B Dividend being paid, divided by (2) $<span id="xdx_90F_eus-gaap--PreferredStockDividendRatePerDollarAmount_c20220101__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYcK57Wp0NYj" title="Stock dividend">0.25</span> (the “Stock Dividend”). The Stock Dividend shall be paid via the issuance to the applicable Series B Holder of the applicable shares of common stock via book entry in the books and records of the Company. At March 31, 2022, cumulative unpaid dividends on the Series B Preferred Stock amounted to $<span id="xdx_906_eus-gaap--DividendsPayableCurrent_iI_pp0p0_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJGnlsWTNj5b" title="Cummulative unpaid dividends">361,712</span>. <span id="xdx_90B_eus-gaap--CommonStockDividendsShares_do_c20220101__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zI4BAzyiJxI5" title="Common stock issued in satisfaction of preferred stock dividend">No</span> common stock has been issued as of March 31, 2022 in satisfaction of the preferred stock dividend.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><i><span style="text-decoration: underline">Voting Rights</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each share of Series B Preferred Stock shall have a number of votes on any matter submitted to the holders of the Company’s common stock, or any class thereof, for a vote, equal to the number of Conversion Shares into which the Series B Preferred Stock is then convertible, and shall vote together with the common stock, or any class thereof, as applicable, as one class on such matter for as long as the share of Series B Preferred Stock is issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> 264894 24900000 0.001 4000000 0.08 0.25 361712 0 <p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpv0ku43RmFk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 7 – <span><span id="xdx_82A_zvDdI7eUPRza">Related Party Transactions</span></span> </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to an agreement dated June 2013 and amended in July 2021, TBG Holdings Corp. (“TBG”), was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. TBG is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and director, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer and director, and a significant stockholder of the Company. Effective on June 14, 2022, Neil Swartz voluntarily resigned as CEO at MediXall Group, Inc. and the Company appointed Noel J. Guillama-Alvarez as his successor. Under this agreement, we pay TBG a monthly fee of $<span id="xdx_90D_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pp0p0_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGMember_zSDkFRjcGoL3" title="Fee for consulting and administrative services">40,000</span>. In April 2021, we entered into an additional agreement with TBG to provide management services specifically to our Health Karma subsidiary. Under this new agreement, we pay TBG an additional monthly fee of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20210401__20210430_pp0p0" title="Debt Instrument, Periodic Payment">40,000</span>. During the three months ended March 31, 2022 and 2021, the Company expensed $<span id="xdx_90D_eus-gaap--ManagementFeeExpense_pp0p0_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGMember_zmnaqbLgOkn1" title="Management fee - related party">240,000</span> and $<span id="xdx_905_eus-gaap--ManagementFeeExpense_pp0p0_c20210101__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGMember_zSM1oKUObGc4" title="Management fee - related party">120,000</span>, respectively, of related party management fees related to these agreements. At March 31, 2022 and December 31, 2021, the Company had prepaid management fees related to the aforementioned agreement with TBG amounting to $<span id="xdx_907_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGMember_z38faXgm5r12" title="Prepaid expenses- related party">116,413</span> and $<span id="xdx_908_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGMember_zPrJ8OgqBSC3" title="Prepaid expenses- related party">276,043</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the three month period ended March 31, 2021, the Company paid $<span id="xdx_908_eus-gaap--MarketingExpense_pp0p0_c20210101__20210331_zhI8NqJWiUq" title="Marketing and Consulting expenses">94,000</span> in marketing and consulting expenses to two companies which are owned by the former president of Turnkey a related party. There was <span id="xdx_906_eus-gaap--MarketingExpense_pp0p0_do_c20220101__20220331_zbbs1VJLdKi1" title="Marketing and Consulting expenses">no</span> such fee during the three month period ended March 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">R3 Accounting LLC (“R3”), owned by Mr. Hart, provides accounting, tax and bookkeeping services to the Company. During the three months ended March 31, 2022 and 2021, the Company expensed $<span id="xdx_90D_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pp0p0_c20220101__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zA4BY1HnpJw4" title="Fee for consulting and administrative services">120,000</span> and $<span id="xdx_903_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pp0p0_c20210101__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_z3KU4rKfctBa" title="Fee for consulting and administrative services">70,038</span>, respectively, related to R3 services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company received short term cash advances during 2021 from Turnkey. The advances are due on demand, unsecured, and do not bear any interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prepaid expenses (accounts payable and accrued expenses) to related parties are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zpHelEefyCR5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zkugscxwHWe8" style="display: none">Schedule of prepaid expenses (accounts payable and accrued expenses) to related parties</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold">Related Party</td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>At</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1pt; font-size: 8pt"> </td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>At</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1pt; font-size: 8pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; font-size: 10pt">TBG</td><td style="width: 1%; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--PrepaidExpenseCurrent_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGHoldingsCorpMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Prepaid expenses- related party">116,413</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--PrepaidExpenseCurrent_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGHoldingsCorpMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Prepaid expenses- related party">276,043</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Turnkey</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TurnkeyMember_zYlYBz0oiX1j" style="font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(549,150</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TurnkeyMember_z0RrEbknlL9i" style="font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(549,150</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 10pt; padding-bottom: 1pt">R3</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zlW1S41hgF1k" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(40,052</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zLXreaodtPck" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(18,052</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_c20220331_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Due from (to) related party">(472,789</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_pp0p0_c20211231_zolVtfaI7CBb" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Due from (to) related party">(291,159</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> 40000 40000 240000 120000 116413 276043 94000 0 120000 70038 <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zpHelEefyCR5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zkugscxwHWe8" style="display: none">Schedule of prepaid expenses (accounts payable and accrued expenses) to related parties</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold">Related Party</td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>At</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p></td><td style="padding-bottom: 1pt; font-size: 8pt"> </td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>At</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31,</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1pt; font-size: 8pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; font-size: 10pt">TBG</td><td style="width: 1%; font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--PrepaidExpenseCurrent_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGHoldingsCorpMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Prepaid expenses- related party">116,413</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--PrepaidExpenseCurrent_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGHoldingsCorpMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Prepaid expenses- related party">276,043</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Turnkey</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_982_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TurnkeyMember_zYlYBz0oiX1j" style="font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(549,150</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TurnkeyMember_z0RrEbknlL9i" style="font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(549,150</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 10pt; padding-bottom: 1pt">R3</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zlW1S41hgF1k" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(40,052</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zLXreaodtPck" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(18,052</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_c20220331_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Due from (to) related party">(472,789</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_pp0p0_c20211231_zolVtfaI7CBb" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Due from (to) related party">(291,159</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr> </table> 116413 276043 549150 549150 40052 18052 -472789 -291159 <p id="xdx_806_ecustom--SeniorConvertibleDebenturesAndWarrantsTextBlock_zln03Z6aYLrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Note 8 – <span id="xdx_82A_zbMvrw3C2eKd">Senior Convertible Debentures and Warrants</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3pc"><span id="xdx_906_ecustom--SecuritiesPurchaseAgreementDescription_c20220301__20220331_zQQs7EuPvYD1" title="Securities purchase agreement, description">In March 2022, the Company entered into a securities purchase agreement in which the Company maximum offering amount is $5,000,000. For every $1,000 invested in the offering, the Investors will receive a Debenture with a face amount of $1,000 and Warrants to purchase 350 Common Shares at an exercise price of $1.50 per share expiring on April 30, 2027.</span> Pursuant to this agreement, the Company has entered into three convertible debentures totaling $<span id="xdx_90A_eus-gaap--ConvertibleDebt_iI_c20220331__us-gaap--LongtermDebtTypeAxis__custom--ThreeConvertibleLoanDebenturesMember_zZ989ngasMOf" title="Convertible loan">450,000</span> with an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20220331__us-gaap--LongtermDebtTypeAxis__custom--ThreeConvertibleLoanDebenturesMember_zut1d5RzXqga" title="Interest rate">8</span>% maturing on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20220301__20220331__us-gaap--LongtermDebtTypeAxis__custom--ThreeConvertibleLoanDebenturesMember_zMfXkzbkYGm7" title="Maturity date">September 30, 2023</span>. The outstanding debentures are convertible into shares of common stock at $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20220301__20220331_zWj1INSAoxcf" title="Convertible stock per share">2.00</span> per share. The debentures may be converted at any time after the issuance date until the debentures are paid off.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The Company issued warrants to acquire up to an aggregate <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220331_zzBzi2MT7Ik5" title="Issuance of warrants">157,500</span> shares of the Company’s common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220331_zqJOyZ2WdtRi" title="Exercise price">1.50</span> per share. Each Warrant is exercisable by the Investor beginning on the effective date through the fifth-year anniversary thereof.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The fair value of each warrant issued during the three months ended March 31, 2022 was estimated on the date of issuance using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3pc; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOM213gEn9Ke" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - Senior Convertible Debentures and Warrants (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: justify"><span id="xdx_8BA_zyBXDcBePDoa" style="display: none">Schedule of assumptions</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 87%; text-align: justify">Stock price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_c20220331_z2XaZewp9h1" style="width: 10%; text-align: right" title="Stock price">0.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331_zjFEoml1NP07" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20220331_zkdQBFKyPlC8" title="Risk-free interest rate">2.10</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20220101__20220331_zdahFnOBTFGf" title="Expected dividend yield">—</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: justify">Expected stock volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20220331_zEItu33Jceaf" title="Expected stock volatility">81.03</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: justify">Expected life in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331_zP6nRhxHFdwa" title="Expected life in years">5.00</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The expected life was based on the average life of the warrants. Expected volatility is based on historical volatility of Company's common stock. The risk-free rate for periods within the contractual life of the warrants is based on the U.S. Treasury yield curve in effect at the time of issuance. The dividend yield assumption is based on the Company's expectation of dividend payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The result was a fair value of $<span id="xdx_90B_ecustom--FairValueOfWarrant_c20220101__20220331_z7CCRUUknGQl">0.16 </span>per warrant or $<span id="xdx_90C_ecustom--AggregateAmount_iI_c20220331_zB42qECQnvOl">25,129</span> in aggregate. This fair value was reduced with the relative fair value to $<span id="xdx_904_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_c20220331_zAmEsZEKSSna" title="Fair value reduced amount">23,800</span>. During the three-month ended March 31, 2022, the Company amortized $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_c20220101__20220331_z6cO7Gy1mEOa">680</span>, of the debt discount to interest expense.</p> In March 2022, the Company entered into a securities purchase agreement in which the Company maximum offering amount is $5,000,000. For every $1,000 invested in the offering, the Investors will receive a Debenture with a face amount of $1,000 and Warrants to purchase 350 Common Shares at an exercise price of $1.50 per share expiring on April 30, 2027. 450000 0.08 2023-09-30 2.00 157500 1.50 <table cellpadding="0" cellspacing="0" id="xdx_88D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zOM213gEn9Ke" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - Senior Convertible Debentures and Warrants (Details)"> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: justify"><span id="xdx_8BA_zyBXDcBePDoa" style="display: none">Schedule of assumptions</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 87%; text-align: justify">Stock price</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_c20220331_z2XaZewp9h1" style="width: 10%; text-align: right" title="Stock price">0.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331_zjFEoml1NP07" style="text-align: right" title="Exercise price">1.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220101__20220331_zkdQBFKyPlC8" title="Risk-free interest rate">2.10</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20220101__20220331_zdahFnOBTFGf" title="Expected dividend yield">—</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="text-align: justify">Expected stock volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220101__20220331_zEItu33Jceaf" title="Expected stock volatility">81.03</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: transparent"> <td style="text-align: justify">Expected life in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220331_zP6nRhxHFdwa" title="Expected life in years">5.00</span></td><td style="text-align: left"> </td></tr> </table> 0.40 1.50 0.0210 0 0.8103 P5Y 0.16 25129 23800 680 EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 67 181 1 false 15 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://medixall.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://medixall.com/role/CondendsedConsolidatedBalanceSheets CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://medixall.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Sheet http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical) Sheet http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Nature of Operation Sheet http://medixall.com/role/OrganizationAndNatureOfOperation Organization and Nature of Operation Notes 8 false false R9.htm 00000009 - Disclosure - Asset Acquisition Sheet http://medixall.com/role/AssetAcquisition Asset Acquisition Notes 9 false false R10.htm 00000010 - Disclosure - Going Concern Sheet http://medixall.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 00000011 - Disclosure - Summary of Significant Accounting Policies Sheet http://medixall.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 00000012 - Disclosure - Right-to-use Intellectual Property Sheet http://medixall.com/role/Right-to-useIntellectualProperty Right-to-use Intellectual Property Notes 12 false false R13.htm 00000013 - Disclosure - Preferred Stock Sheet http://medixall.com/role/PreferredStock Preferred Stock Notes 13 false false R14.htm 00000014 - Disclosure - Related Party Transactions Sheet http://medixall.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 00000015 - Disclosure - Senior Convertible Debentures and Warrants Sheet http://medixall.com/role/SeniorConvertibleDebenturesAndWarrants Senior Convertible Debentures and Warrants Notes 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://medixall.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://medixall.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Right-to-use Intellectual Property (Tables) Sheet http://medixall.com/role/Right-to-useIntellectualPropertyTables Right-to-use Intellectual Property (Tables) Tables http://medixall.com/role/Right-to-useIntellectualProperty 18 false false R19.htm 00000019 - Disclosure - Related Party Transactions (Tables) Sheet http://medixall.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://medixall.com/role/RelatedPartyTransactions 19 false false R20.htm 00000020 - Disclosure - Senior Convertible Debentures and Warrants (Tables) Sheet http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsTables Senior Convertible Debentures and Warrants (Tables) Tables http://medixall.com/role/SeniorConvertibleDebenturesAndWarrants 20 false false R21.htm 00000021 - Disclosure - Asset Acquisition (Details Narrative) Sheet http://medixall.com/role/AssetAcquisitionDetailsNarrative Asset Acquisition (Details Narrative) Details http://medixall.com/role/AssetAcquisition 21 false false R22.htm 00000022 - Disclosure - Going Concern (Details Narrative) Sheet http://medixall.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://medixall.com/role/GoingConcern 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details) Details http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details) Details http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Right-to-use Intellectual Property (Schedule of Right-to-use Intellectual Property) (Details) Sheet http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfRight-to-useIntellectualPropertyDetails Right-to-use Intellectual Property (Schedule of Right-to-use Intellectual Property) (Details) Details http://medixall.com/role/Right-to-useIntellectualPropertyTables 26 false false R27.htm 00000027 - Disclosure - Right-to-use Intellectual Property (Schedule of amortization expense for right-to-use intellectual property) (Details) Sheet http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfAmortizationExpenseForRight-to-useIntellectualPropertyDetails Right-to-use Intellectual Property (Schedule of amortization expense for right-to-use intellectual property) (Details) Details http://medixall.com/role/Right-to-useIntellectualPropertyTables 27 false false R28.htm 00000028 - Disclosure - Preferred Stock (Details Narrative) Sheet http://medixall.com/role/PreferredStockDetailsNarrative Preferred Stock (Details Narrative) Details http://medixall.com/role/PreferredStock 28 false false R29.htm 00000029 - Disclosure - Related Party Transactions (Details) Sheet http://medixall.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://medixall.com/role/RelatedPartyTransactionsTables 29 false false R30.htm 00000030 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://medixall.com/role/RelatedPartyTransactionsTables 30 false false R31.htm 00000031 - Disclosure - Senior Convertible Debentures and Warrants (Details) Sheet http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetails Senior Convertible Debentures and Warrants (Details) Details http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsTables 31 false false R32.htm 00000032 - Disclosure - Senior Convertible Debentures and Warrants (Details Narrative) Sheet http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative Senior Convertible Debentures and Warrants (Details Narrative) Details http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsTables 32 false false All Reports Book All Reports mdxl_10q-033122.htm mdxl-20220331.xsd mdxl-20220331_cal.xml mdxl-20220331_def.xml mdxl-20220331_lab.xml mdxl-20220331_pre.xml mdxl_ex31z1.htm mdxl_ex31z2.htm mdxl_ex32z1.htm mdxl_ex32z2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mdxl_10q-033122.htm": { "axisCustom": 0, "axisStandard": 5, "contextCount": 67, "dts": { "calculationLink": { "local": [ "mdxl-20220331_cal.xml" ] }, "definitionLink": { "local": [ "mdxl-20220331_def.xml" ] }, "inline": { "local": [ "mdxl_10q-033122.htm" ] }, "labelLink": { "local": [ "mdxl-20220331_lab.xml" ] }, "presentationLink": { "local": [ "mdxl-20220331_pre.xml" ] }, "schema": { "local": [ "mdxl-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 271, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 17, "http://medixall.com/20220331": 11, "http://xbrl.sec.gov/dei/2022": 5, "total": 33 }, "keyCustom": 32, "keyStandard": 149, "memberCustom": 9, "memberStandard": 5, "nsprefix": "mdxl", "nsuri": "http://medixall.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://medixall.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Going Concern", "role": "http://medixall.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Summary of Significant Accounting Policies", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Right-to-use Intellectual Property", "role": "http://medixall.com/role/Right-to-useIntellectualProperty", "shortName": "Right-to-use Intellectual Property", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Preferred Stock", "role": "http://medixall.com/role/PreferredStock", "shortName": "Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Related Party Transactions", "role": "http://medixall.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mdxl:SeniorConvertibleDebenturesAndWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Senior Convertible Debentures and Warrants", "role": "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrants", "shortName": "Senior Convertible Debentures and Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mdxl:SeniorConvertibleDebenturesAndWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mdxl:ScheduleOfRightToUseIntellectualPropertyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Right-to-use Intellectual Property (Tables)", "role": "http://medixall.com/role/Right-to-useIntellectualPropertyTables", "shortName": "Right-to-use Intellectual Property (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mdxl:ScheduleOfRightToUseIntellectualPropertyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Related Party Transactions (Tables)", "role": "http://medixall.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "shortName": "CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "mdxl:SeniorConvertibleDebenturesAndWarrantsTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Senior Convertible Debentures and Warrants (Tables)", "role": "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsTables", "shortName": "Senior Convertible Debentures and Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "mdxl:SeniorConvertibleDebenturesAndWarrantsTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "mdxl:AssetAcquisitionDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-01-17", "decimals": "0", "first": true, "lang": null, "name": "mdxl:IntellectualPropertyValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Asset Acquisition (Details Narrative)", "role": "http://medixall.com/role/AssetAcquisitionDetailsNarrative", "shortName": "Asset Acquisition (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "mdxl:AssetAcquisitionDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-01-17", "decimals": "0", "first": true, "lang": null, "name": "mdxl:IntellectualPropertyValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Going Concern (Details Narrative)", "role": "http://medixall.com/role/GoingConcernDetailsNarrative", "shortName": "Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails", "shortName": "Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_SeriesAPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails", "shortName": "Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_SeriesAPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "mdxl:ScheduleOfRightToUseIntellectualPropertyTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Right-to-use Intellectual Property (Schedule of Right-to-use Intellectual Property) (Details)", "role": "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfRight-to-useIntellectualPropertyDetails", "shortName": "Right-to-use Intellectual Property (Schedule of Right-to-use Intellectual Property) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "mdxl:ScheduleOfRightToUseIntellectualPropertyTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "mdxl:ScheduleOfAmortizationExpenseForTheRightToUseIntellectualPropertyTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Right-to-use Intellectual Property (Schedule of amortization expense for right-to-use intellectual property) (Details)", "role": "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfAmortizationExpenseForRight-to-useIntellectualPropertyDetails", "shortName": "Right-to-use Intellectual Property (Schedule of amortization expense for right-to-use intellectual property) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "mdxl:ScheduleOfAmortizationExpenseForTheRightToUseIntellectualPropertyTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31_us-gaap_SeriesAPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Preferred Stock (Details Narrative)", "role": "http://medixall.com/role/PreferredStockDetailsNarrative", "shortName": "Preferred Stock (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31_us-gaap_SeriesAPreferredStockMember", "decimals": "INF", "lang": null, "name": "mdxl:ConvertiblePreferredStockTotalSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Related Party Transactions (Details)", "role": "http://medixall.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "mdxl:ConvertibleDebtNetOfDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "mdxl:ConvertibleDebtNetOfDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2021-04-012021-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2021-04-012021-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "mdxl:SeniorConvertibleDebenturesAndWarrantsTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Senior Convertible Debentures and Warrants (Details)", "role": "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetails", "shortName": "Senior Convertible Debentures and Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "mdxl:SeniorConvertibleDebenturesAndWarrantsTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "mdxl:SeniorConvertibleDebenturesAndWarrantsTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-03-012022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mdxl:SecuritiesPurchaseAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Senior Convertible Debentures and Warrants (Details Narrative)", "role": "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative", "shortName": "Senior Convertible Debentures and Warrants (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "mdxl:SeniorConvertibleDebenturesAndWarrantsTextBlock", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-03-012022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mdxl:SecuritiesPurchaseAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2020-12-31_custom_SeriesAVotingPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "role": "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "AsOf2020-12-31_custom_SeriesAVotingPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical)", "role": "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Organization and Nature of Operation", "role": "http://medixall.com/role/OrganizationAndNatureOfOperation", "shortName": "Organization and Nature of Operation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mdxl:AssetAcquisitionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Asset Acquisition", "role": "http://medixall.com/role/AssetAcquisition", "shortName": "Asset Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-033122.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mdxl:AssetAcquisitionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 15, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r310", "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "mdxl_AdditionalSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional shares issued" } } }, "localname": "AdditionalSharesIssued", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mdxl_AggregateAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[custom:AggregateAmount-0]" } } }, "localname": "AggregateAmount", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mdxl_AmortizationOfDebentureDiscounts": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "AmortizationOfDebentureDiscounts", "negatedLabel": "Amortization of debenture discounts" } } }, "localname": "AmortizationOfDebentureDiscounts", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_AmortizationOfRightofuseOperatingLeaseAsset": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization of right-of-use operating lease asset" } } }, "localname": "AmortizationOfRightofuseOperatingLeaseAsset", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_AmortizationOfRighttouseIntellectualProperty": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization of right-to-use intellectual property" } } }, "localname": "AmortizationOfRighttouseIntellectualProperty", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_AssetAcquisitionDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AssetAcquisitionDisclosureTextBlock", "verboseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionDisclosureTextBlock", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/AssetAcquisition" ], "xbrltype": "textBlockItemType" }, "mdxl_BasicAndDilutedLps": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted LPS" } } }, "localname": "BasicAndDilutedLps", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "sharesItemType" }, "mdxl_CommonStockIssuedInExchangeForRighttouseIntellectualProperty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued in exchange for right-to-use intellectual property" } } }, "localname": "CommonStockIssuedInExchangeForRighttouseIntellectualProperty", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "mdxl_CommonStockIssuedInExchangeForRighttouseIntellectualPropertyShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued in exchange for right-to-use intellectual property, Shares" } } }, "localname": "CommonStockIssuedInExchangeForRighttouseIntellectualPropertyShares", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "mdxl_ConvertibleDebtNetOfDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net of discount" } } }, "localname": "ConvertibleDebtNetOfDiscount", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "mdxl_ConvertiblePreferredStockTotalSharesIssuedUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for total shares of convertible preferred stock that is converted.", "label": "Number of common stock issuable for total shares of convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockTotalSharesIssuedUponConversion", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mdxl_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "stringItemType" }, "mdxl_DisclosureAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Acquisition" } } }, "localname": "DisclosureAssetAcquisitionAbstract", "nsuri": "http://medixall.com/20220331", "xbrltype": "stringItemType" }, "mdxl_DisclosureSeniorConvertibleDebenturesAndWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Convertible Debentures And Warrants" } } }, "localname": "DisclosureSeniorConvertibleDebenturesAndWarrantsAbstract", "nsuri": "http://medixall.com/20220331", "xbrltype": "stringItemType" }, "mdxl_DiscountIssuedWithConvertibleDebentures": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Discount issued with Convertible Debentures" } } }, "localname": "DiscountIssuedWithConvertibleDebentures", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_EarningPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic and diluted" } } }, "localname": "EarningPerShareBasicAndDiluted", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "mdxl_EarningsPerSharesBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted LPS Computation" } } }, "localname": "EarningsPerSharesBasicAndDilutedAbstract", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "stringItemType" }, "mdxl_FairValueOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:FairValueOfWarrant]" } } }, "localname": "FairValueOfWarrant", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "mdxl_FairValueOfWarrantsIssuedWithConvertibleDebentures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of Warrants issued with Convertible Debentures" } } }, "localname": "FairValueOfWarrantsIssuedWithConvertibleDebentures", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "mdxl_IncreaseDecreaseInPrepaidExpensesRelatedParty": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInPrepaidExpensesRelatedParty", "verboseLabel": "Prepaid expenses - related party" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesRelatedParty", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_IntellectualPropertyValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Intellectual property value" } } }, "localname": "IntellectualPropertyValue", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mdxl_IssuanceOfCommonStockInExchangeForOfRighttouseIntellectualProperty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of Common Stock in exchange for of the Right-to-Use Intellectual Property" } } }, "localname": "IssuanceOfCommonStockInExchangeForOfRighttouseIntellectualProperty", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_LossAvailableToCommonStockholders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loss available to common stockholders" } } }, "localname": "LossAvailableToCommonStockholders", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "monetaryItemType" }, "mdxl_ManagementFeeRelatedParty": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Management fees - related party" } } }, "localname": "ManagementFeeRelatedParty", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "mdxl_MediXallGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Medi Xall Group Inc [Member]" } } }, "localname": "MediXallGroupIncMember", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "mdxl_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "stringItemType" }, "mdxl_ProceedsReceivedFromSaleOfPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Proceeds received from sale of Preferred Stock" } } }, "localname": "ProceedsReceivedFromSaleOfPreferredStock", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "mdxl_ProceedsReceivedFromSaleOfPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds received from sale of Preferred Stock, Shares" } } }, "localname": "ProceedsReceivedFromSaleOfPreferredStockShares", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "mdxl_ProfessionalFeesRelatedParty": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Professional fees - related party" } } }, "localname": "ProfessionalFeesRelatedParty", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "mdxl_R3AccountingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining to R3Accounting, LLC.", "label": "R3 Accounting LLC [Member]" } } }, "localname": "R3AccountingLLCMember", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mdxl_RightsToUseIntellectualPropertyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights-to-use Intellectual Property" } } }, "localname": "RightsToUseIntellectualPropertyPolicyTextBlock", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mdxl_ScheduleOfAmortizationExpenseForTheRightToUseIntellectualPropertyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of amortization expense for right-to-use intellectual property" } } }, "localname": "ScheduleOfAmortizationExpenseForTheRightToUseIntellectualPropertyTableTextBlock", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyTables" ], "xbrltype": "textBlockItemType" }, "mdxl_ScheduleOfRightToUseIntellectualPropertyTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Right-to-use Intellectual Property" } } }, "localname": "ScheduleOfRightToUseIntellectualPropertyTableTextBlock", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyTables" ], "xbrltype": "textBlockItemType" }, "mdxl_SecuritiesPurchaseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Securities purchase agreement, description" } } }, "localname": "SecuritiesPurchaseAgreementDescription", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "mdxl_SeniorConvertibleDebenturesAndWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Convertible Debentures and Warrants [Member]" } } }, "localname": "SeniorConvertibleDebenturesAndWarrantsMember", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "mdxl_SeniorConvertibleDebenturesAndWarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeniorConvertibleDebenturesAndWarrantsPolicyTextBlock", "verboseLabel": "Senior Convertible Debentures and Warrants" } } }, "localname": "SeniorConvertibleDebenturesAndWarrantsPolicyTextBlock", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mdxl_SeniorConvertibleDebenturesAndWarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Convertible Debentures and Warrants" } } }, "localname": "SeniorConvertibleDebenturesAndWarrantsTextBlock", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrants" ], "xbrltype": "textBlockItemType" }, "mdxl_SeriesAVotingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Voting Preferred Stock [Member]" } } }, "localname": "SeriesAVotingPreferredStockMember", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "mdxl_SeriesBVotingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Voting Preferred Stock [Member]" } } }, "localname": "SeriesBVotingPreferredStockMember", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "mdxl_TBGHoldingsCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tbg holdings corp member.", "label": "T B G Holdings Corp [Member]" } } }, "localname": "TBGHoldingsCorpMember", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "mdxl_TBGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "T B G [Member]" } } }, "localname": "TBGMember", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mdxl_ThreeConvertibleLoanDebenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Convertible Loan Debentures [Member]" } } }, "localname": "ThreeConvertibleLoanDebenturesMember", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mdxl_TurnkeyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Turnkey [Member]" } } }, "localname": "TurnkeyMember", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "mdxl_WebsiteAndDevelopmentCosts": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "WebsiteAndDevelopmentCosts", "negatedLabel": "Website and development costs" } } }, "localname": "WebsiteAndDevelopmentCosts", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_WeightedAverageNumberOfCommonSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfCommonSharesOutstanding", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "sharesItemType" }, "mdxl_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodsBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding during the periods - basic and diluted" } } }, "localname": "WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodsBasicAndDiluted", "nsuri": "http://medixall.com/20220331", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r23", "r62", "r247", "r248" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued expenses - related party", "negatedLabel": "Accounts payable and accrued expenses - related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r253" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r65", "r66", "r67", "r203", "r204", "r205", "r225" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r43", "r50", "r168", "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r9", "r60", "r108", "r111", "r117", "r124", "r139", "r140", "r141", "r143", "r144", "r145", "r146", "r147", "r148", "r150", "r151", "r219", "r222", "r228", "r251", "r253", "r270", "r281" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r22", "r60", "r124", "r139", "r140", "r141", "r143", "r144", "r145", "r146", "r147", "r148", "r150", "r151", "r219", "r222", "r228", "r251", "r253" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareNet": { "auth_ref": [ "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.", "label": "Capitalized Computer Software, Net", "verboseLabel": "Website and development costs" } } }, "localname": "CapitalizedComputerSoftwareNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r7", "r253", "r294", "r295" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r47", "r52", "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r47", "r229" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r12", "r13", "r14", "r58", "r60", "r80", "r81", "r86", "r89", "r90", "r94", "r95", "r96", "r124", "r139", "r144", "r145", "r146", "r150", "r151", "r178", "r179", "r182", "r183", "r185", "r228", "r315" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative", "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Issuance of warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common stock issued in satisfaction of preferred stock dividend" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r65", "r66", "r225" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r185" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r253" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.001 par value 750,000,000 shares authorized; 115,901,920 and 110,864,595 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r99", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Risks and Uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r55", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r11", "r271", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible loan" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Senior Convertible Debentures, net of discount of $23,800" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Fair value reduced amount" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.", "label": "Convertible stock per share" } } }, "localname": "DebtInstrumentConvertibleStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r28", "r170", "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r29", "r155", "r227" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r30", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r30", "r59", "r63", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r186", "r189", "r190", "r191", "r236", "r237", "r238", "r239", "r279" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r50", "r135" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Cummulative unpaid dividends" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r192", "r277" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Less preferred stock dividends" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r192", "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "Series B Preferred Stock Dividends" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r91", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r35", "r36", "r37", "r65", "r66", "r67", "r69", "r74", "r76", "r93", "r125", "r185", "r192", "r203", "r204", "r205", "r215", "r216", "r225", "r230", "r231", "r232", "r233", "r234", "r235", "r242", "r289", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r8", "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfRight-to-useIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfAmortizationExpenseForRight-to-useIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfAmortizationExpenseForRight-to-useIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfAmortizationExpenseForRight-to-useIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfAmortizationExpenseForRight-to-useIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfAmortizationExpenseForRight-to-useIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfAmortizationExpenseForRight-to-useIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r132", "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfRight-to-useIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r132", "r255" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Net carrying amount", "verboseLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfAmortizationExpenseForRight-to-useIntellectualPropertyDetails", "http://medixall.com/role/Right-to-useIntellectualPropertyScheduleOfRight-to-useIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r128", "r130" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Website and Development Costs" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r134", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Recoverability of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r39", "r108", "r110", "r113", "r116", "r118", "r269", "r273", "r275", "r287" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r61", "r75", "r76", "r107", "r210", "r217", "r218", "r288" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r34", "r208", "r209", "r211", "r212", "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r49" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r49" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "verboseLabel": "Accounts payable and accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilities": { "auth_ref": [ "r49" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.", "label": "Increase (Decrease) in Operating Liabilities", "verboseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r49" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Right-to-use Intellectual Property" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/Right-to-useIntellectualProperty" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r129", "r131" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Website and development costs" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r50" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Common stock issued as compensation for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r41" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Personnel related expenses" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r60", "r112", "r124", "r139", "r140", "r141", "r144", "r145", "r146", "r147", "r148", "r150", "r151", "r220", "r222", "r223", "r228", "r251", "r252" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r60", "r124", "r228", "r253", "r272", "r284" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r27", "r60", "r124", "r139", "r140", "r141", "r144", "r145", "r146", "r147", "r148", "r150", "r151", "r220", "r222", "r223", "r228", "r251", "r252", "r253" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r30", "r138" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ManagementFeeExpense": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).", "label": "Management fee - related party" } } }, "localname": "ManagementFeeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingExpense": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.", "label": "Marketing and Consulting expenses" } } }, "localname": "MarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r47" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r47" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r47", "r48", "r51" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r32", "r33", "r37", "r40", "r51", "r60", "r68", "r70", "r71", "r72", "r73", "r75", "r76", "r87", "r108", "r110", "r113", "r116", "r118", "r124", "r139", "r140", "r141", "r144", "r145", "r146", "r147", "r148", "r150", "r151", "r226", "r228", "r274", "r286" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r70", "r71", "r72", "r73", "r77", "r78", "r88", "r90", "r108", "r110", "r113", "r116", "r118" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r79", "r82", "r83", "r84", "r85", "r88", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses [Default Label]", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r241" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r241" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r240" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use-operating lease asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization and Nature of Operation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/OrganizationAndNatureOfOperation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r21", "r253" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Rights-to-use-intellectual property" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r20", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses- related party" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expense classified as other.", "label": "Other selling, general and administrative" } } }, "localname": "OtherSellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "The amount per share used to calculated dividend payments on preferred stock.", "label": "Stock dividend" } } }, "localname": "PreferredStockDividendRatePerDollarAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Dividend rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r178" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Convertible Preferred stock, par value (in dollars per share)", "verboseLabel": "Convertible Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Convertible Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13", "r178" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Convertible Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Convertible Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "Preferred Stock" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/PreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r20", "r126", "r127" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses - related party", "verboseLabel": "Prepaid expenses- related party" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r44" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from the sale of common stock, net of offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r45" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from issuance of convertible debentures" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r44" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from the sale of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r296", "r297" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r136", "r253", "r276", "r285" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Furniture and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Allowance for Uncollectible Accounts Receivable" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r194", "r245", "r246" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r62", "r142", "r144", "r145", "r149", "r150", "r151", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Due from (to) related party" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Fee for consulting and administrative services" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r194", "r245", "r248", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r243", "r244", "r246", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r192", "r253", "r283", "r292", "r293" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r65", "r66", "r67", "r69", "r74", "r76", "r125", "r203", "r204", "r205", "r215", "r216", "r225", "r289", "r291" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r38", "r60", "r105", "r106", "r109", "r114", "r115", "r119", "r120", "r121", "r124", "r139", "r140", "r141", "r144", "r145", "r146", "r147", "r148", "r150", "r151", "r228", "r275" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of prepaid expenses (accounts payable and accrued expenses) to related parties" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of computation of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r12", "r13", "r14", "r58", "r94", "r95", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r12", "r13", "r185" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r12", "r13", "r185" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r195", "r196", "r197", "r198", "r199", "r202", "r206", "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangements" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SeniorConvertibleDebenturesAndWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r54", "r64" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r12", "r13", "r14", "r58", "r60", "r80", "r81", "r86", "r89", "r90", "r94", "r95", "r96", "r124", "r139", "r144", "r145", "r146", "r150", "r151", "r178", "r179", "r182", "r183", "r185", "r228", "r315" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative", "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r31", "r35", "r36", "r37", "r65", "r66", "r67", "r69", "r74", "r76", "r93", "r125", "r185", "r192", "r203", "r204", "r205", "r215", "r216", "r225", "r230", "r231", "r232", "r233", "r234", "r235", "r242", "r289", "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative", "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r65", "r66", "r67", "r93", "r254" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative", "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock issued for services, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r185", "r192" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of shares issued", "verboseLabel": "Stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/AssetAcquisitionDetailsNarrative", "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r185", "r192" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Proceeds from issue of stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r60", "r123", "r124", "r228", "r253" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' DEFICIT:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r97", "r98", "r100", "r101", "r102", "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r299": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r301": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r302": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r303": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r304": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r305": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r306": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r307": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r308": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r309": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r311": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r312": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r313": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r314": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r315": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r316": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r317": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r318": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r319": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" } }, "version": "2.1" } ZIP 50 0001079973-22-000915-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-22-000915-xbrl.zip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筆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

OEA^<TAJDRNE&]LPZ^FE= M!F7\"(IQ_!,4?*NMV!T;'XK8PL. L?.4*)]=W")!O..%6$,)H^SANW6FD #HK0NWR[.+:VOA%E,K@Q G$K,]\T M6RLYG, %9TE$/ODY:U#DD/B@UBK\NOQZ6[R_^7QZ(FK4B925%R()44$57Q!@ M$O%]&8+LWI@Q/$]F. (NT%!W)$EC<.AQ/P5\QZ>,3;@ZXK%0P9\D/H>O)1B& MG#P=0@P W]*[Q\S;/S']^D@:$I<4ZU'M]$1"G K+QJ&" !3&CP^Y,N[Q Y5=N# /T.9V 1C/CM&,_/L7=%X<:"<49@$K#/"LHO*ZH&F6P 03K M1K/A6?1 % ]0G9ZHZ$611G@H<.,(1PW@.1[\9, N#*B.HU%Q@ O@$3ES"]$, M3V:.F%7Q3 ?I.F;U*0[)VD=#D"+=PH&Q1..= ;A9#.IV15Z$Y8!(X!.[443J MN "5=A1@C&"X3-S-2DX/R8C*ZD"4<= %J &*C@CJL#TBT^*0#=_/*@)A%!FK M5/L,0\ E#N0 )ZE D0" ZOB.WQ?@#![XL8,7.2)?D%EO.1F&QI.88GUZ4IP.CX?( MRYPTUH"&&N+-;M)Z'_Y6$<;Z!Y'X616*I01"P:XB2/P? (T#7U!%,QA,=$^)3];4G@.PC0[Y2O"(J%A-U_4^@ Q* U@ M3W4,S*03OK!S'Q[/8C!R]GUD5QRG)X#/)Z0#:_-3!@?84I^9:_(4\Y,#> TM M:4 *+0#0"4HA@&QBGV[(YDP'(<;+INVSU(MYD3GS)X9\,N,TWKAHP]+>Z/C M-OMY_GDD:B+&QFJ?-&]K:+_ZY?;D,3:^?[K*YQ)/THZ]S#AQCUCVVX*O&6M/ M?K"WM=+X1_.&ATB-+(2QK20@Q_*05$Y-9GYP\H@#L60S$6)A(E3OF(J(Q'1$ M>D!N ']<3T74:.._,;)4:FA)LA)_B+O_XP\<;P# ,A9/,M\ "O*EZ=&>@WAC;I<-*T$=!9@*?$-9HZG'B-V/-)/[LZ3/ MS9Q9IKM Y+GB"#L]M%*[V0>]HP&RR5=:F\>XB;$QMMVFO[&9=MLVB!%D%21. MT\P;M-]$S?:,;=/IEOC@[;: Q&CT!O4XJ23KH('H&Z9DF7J(J&90;,9;DYNW M1VW0BE]S/[-G#+R&V01T ?;J ;L: =Q8^:IR'V^+7Y;Z-W\#=!B#MA<72E?4 M=EZ0QPV#2K5LRSY3",\N4C&WLW-$:,$!HNB8Z[%B]R )5^$.&F$#'."?3"RT6[L,X%5 M&H#M(0YWA]-H6$;<> $-$1%/[*BIG*B!=!@FB0B7MEJZR,0"KD#\[SS/S]S) MN;BU^1N_V18K)J,#/2?56F%R66R-^,24T2KN\ZZX2]%E3K<:0,Q2_N^/$ZX M!WWJ(@@(%!QXV]1%Z1A1 W;H>1S4D'")/D&RI0;M,&&ZG*C2E?OCH.[+"-1' M*MX8)\J;A FFBI_5I89+2GGQ] 0C:S0VG3D$FHM(RX#(M)5'F-7R)/K!1D00 M1.IV+:CFI,VSL)ZBTD[UE+,FWDR3/E]7"O*?%[&A)RT&G\[J3952#\H15(]Z M6)&ZRW[_@/L(?(02UD]X+CB51[\GJM/ ]>.W_B M";2-8^L(FQT.0D(3B(!C LLY 'J [8/@7BHJHXZ>[X"T7RD@Y04%#*4JNT4' MZ9G*3*^#M"?I>NSVGI\,M =^QU%"PC5*R+IY/H?+$;]H-!B1VQ1/3P2$,UQDHWK!O; ?]6L@G<,&M<2I^(BD,'!B>V*="N\ M,]* H[0@MQCV)=M-O/6RX,]9^>;3D[F$L]GU"E^W*W$RML_V###^W(9:@X+( M@5R83M3,SY-K;@RE@^49B#)UP*SN-.<,A1__9[@8YN.E=+%.MP,)3X GU>N# MEZ.H>A3[\$Q'4562384ES%P3S$@*)QM9?3SRT&B;='I"T(">1QA*W.&/,#ZI M1<% #Q#N'0 +,?>G>%C'(TW[:S.Y_?_#(-+-RRF(V#M:CA630F1O@Q*&DQ2< M#L;":L,5T!RPC9$&B" -?4"SP!*0<,Y<*Z_PLDJ0A@,;FJ67%7RKZDCE*&=P M^@Q.3;^."(:-/#8EA6?29L@_G]<%8<;K,>6*L!+0$GP"4MQ"0HYYO3A/6)<< M#KM]#@=;'(<<3HD0&X.@R%ASKLSC3/*/N3]BM=R5)2N,:-J"_EUE8;!=<\_" M;!5)L+@XDYNP^5J*I(LP92(U&L(C)0"KS9& MN>*K^B-CT7*Q$2")_TE>9T/:SBYJ1Z3=J*DNH>X[-(@5F7D184"SZI+X4J)A MWDC>SM3"I$+^#DB*(AL[(%6?O?FSKLU'M8Q\.G1#D] M 2\)YPD6R$%L_(#LTX"*'DGZM'/S__(]!^,,FW-&Q@[BDOKFS%Q]\W0MY?:DELD.7G.JTF"GW6T" MK'R>F3O]LS9H_AS?*S^[Z]5$3T?)MR=WRILDY\97F;MI>^Y JJ53VU=+SZ3R M"LUX.?.GVQU.$>]C%?5TJEA[TGV+96Z*B48QEEQ>7SU]*]&>H-="MW^5?+UM M"-XQNW'E]7+^MHO@97LRXKN3VT:\T./]3X,N4P_+$J1NX";;DP=15V/)W]EJ ML;==HG'/"5I DPC!&/@9T_W*.B@%",\TM^2L_=IB;P.T)]<%K1=OB.G"4/0% M7^NF9Y,.I<)9X#KNN<>]W#^F4!P?M!\,C*T#V[+L&[GFPG:5M?6?X)><)FJU M[ARMQO2_+@1/VK/QW@: *$A2GI5"/GVKI+?,Q(L7 MB&<7!"9,-GL!NT4<\?A3ZC,.H'6TBU2)>O?MYIQ]DB]>R.7.5S'@U"N)Q'&U M@"H.ID-C)]'J.3%->S41#T$J<8SQ1^;1:-(WP*B]-=.ZS=*T\$$=24;(OS"1 M4<))J:8 M5 :B3A*"MOUP;00!#%T>!E1%O9%DADU65LV 2QF*LI'!'E@UKY'%&,# T8;' M_*S2>5RA:,0J*B8;*=BVN_O3> L6,J3"18H6 *?V&B\K5[X2BJ%"*^-P7(8W MC6Q9QC2' ]G7''D:B)' ME,:8'P52%_V"K((;QP%I@0AZ&]( CU8SC$FP;^0S9Z=CX %S05T1YUZ8,>)4 MW!X,$\LZC $H/#W!.'38XMF,23!6Z5%3$BMC3J8Q-XF7.7/GY]&H?S6.OQ-6 MG:2X#G[BFB9^KSPSO-<7I9Q,4&#: D&)Q#+N':=C45_1FR%O%U1 M,@[I4SU5*N!L2'X(]&/8'&7 @*IP@O?C9DYR+3?F]J9'RUYK3ZK"Z'+R,O@K M_XG[;L+9]B1U??7SM9*OL_?XHA1K4Y#TF+&!]8[LN(96RN+IB9L1HCJ,:!^: M)IK?YL3G)71KIVRQR/^+5$UYOF>#B=APT8%WU:Y PIV:N"0).(R M-JQ,CU54[C14ZY: 4 .\<[S$TYU]L#V)USCV/C\_)XJ[VE MGI,=]"-Y=G%'Z6O-_HZ$P'"H9K;J+:E8SZ-UJ#T@#IF1SM5L3A39:>6>R($2 MBE*:B]6TT6!H;O;BS"S)1%,[1OU.+'-&NA:@M66$[3E@,T,\;(O48U*TY[@+46^X) MKV5*7 <6( 6GZ TTG@C29=>#CR.AAY\X9RJXFP^FC(0X#>>X.4W!>PIC[+AJ MI*&/MB,L (IR>8.T25'PWP_@XY#8F')/6O MM/+:&ULXRH3I\=@X'[\C"L81#++-1P(0N0=>JZY-E\$3[\X(UPQ?2\:.&:E[ M$$9T#U]&>!VDNMDH1@#]'#7%$-/@A6X]Y$FL!)](8S."(46?IE],IZ,[(**8-Y%U:RE>$7@$.AHX? F/FY*0H?IN9T15AGF(6R[ MHB2*$Q.3+ IXD0/' _P#240OR QQ+-%!MI/?K3$ MBW N&05#8NY;BG@'[@E)8V,R4>[3;32"(-MH$;L@3"$T19AJS.EU5N2\J DW M1H=M*')8VJPSPQX6Z%@1O1IGH&G4C(?H3J-F7*?"]VSOX;#;5JZ' MTP+'ZEE-BW)*1 =X22T6YPI]5[[?GB2SXUZ^V'IXJJ1\]\/B[B^.V/1(-:F00O@0"O4UJ/ZF]?K$7=!F:JUFW#4WRV3$$HS6 MQ\5M A%$LY8N/^H!8(Q5K&658I*$DD#5HXXR26OCE26;T(_IEV8KWDVE^C[$%\:<&V\Q9UVWF$OM MR96BBO%^0DUG=[S%G&]/V/Y3[NGAH5Q\$0ZG[5;:SXUDT$&/S6:WDI MX*WD2@5E[O]6!UNN-[^7#VDE.M2?C7[>_G]]2R9M+ M=FLYFI7@?>S0DG,BLDY]@X:H/17 D1=U_-N<*H_:X4HVS.W/([/3$?.5J'MR+CBK<6][;8_S(M+F-XVG^2P5^6/M01HA>'V0(1,1*K9Y*QB%F/E$A^L].'?&!44-X9D;2H&3!C)[>+5%*ZRKVY9AI5 M9#^D;O4,H!ZW48/*D\95KSC+3S<;%[;?:<81IL$#+,N&4APCF2-!+GY#Y70S M[C9K>?&U 31C)AJ0D%U W."+1 0DH6'!1A=A[9N2.MT7I&IHMON5BDN \!XM M0P,:LM.,VQ_1$RH* -W%/5JS@'B?5\+JO&MD:A;G)XC!K]/L"2Y" M%LY/3UJVU*(\\Z)! WMRR$(UR63P2@]W,1,8HXW?@.3N(,JQCMX1E--L%-UE MI0?T">E(<(ACK7T?GMY#$P/;>45M*K)S5L_V$-8S=OLHRB;""9VHC453GB1T MP]2RZB%PVIG17Y6HIJ,A/?&B&07<77SXG2&?&TWJ+&$&64&D]GS*C59F#%>C M6]PX-YLIA!H@A!R!I<<)T!MGI@_G_0K0C49?/ *\;/D IR?<< CLJA'>@N%[ M=(EV+4-[X9$N>MCZFL5( )<)$5VIAG"P;UNJU2QC#GY:AXZ0KEG--J*G)XMR M"%#W%8E0;(HS6^8/NT=(1EU1M]*6EM"(\XK07EB?7Z">V9(%\*$;S3#5'M)T MIZF,]&\/Q%PW#PZD8O]0THE]11'HXQCYIBJ@%!I)1@H95(9.>Q^>8SMA@6)H MV2'.3BHC#>>5L=M'N9:<-;009D,70_!E+-[ L(D[>]G'(G((:TX3*T;5RHP6 MMX8B*50P7.>X4,\ SSZHOK@.66'P645 DBOL!'2PVR3);H-60%$WB'&NW0+9 MR=(M708FG1TN?5IS,Z!GJ/1%I:1Q1YU(YO7,N'&S]9+D&$[LX3 M!L)](D$E2]BX1NSSB/)\=5+$7@ 7F>[E4R%[/PX>F$P-ZQ>R@V4A'0O9P&S/;'\Y MNR.X*HDZ+'B8'NAA33?V=YP\E*,-DQIT,[HQY7;O\=+*=]N3I]:;-"DJ=6&X M?;YG/G#"Z;&7YUK^I27<3C)G%P8XC V>=Q\_&;4$N,;16Y.SNR'-T'\BH4N^ M>4=^0AS4O /I8)/16(XQ$4EV>@N*3"[7,QKW%D@W(]P"BNRLS63NP;J"S1., MTVC4#\/C?N(5TAM,?$%8X(R9"TPZEJ:S+_:77FA78&^02W]G%Z,+8DTTZRR] M4\VT,6_$3(V@:<\+L@4[W?# CIF,&R22U@#440$5+ AO'. >MUCE\V0+V?$A4ESM M=5+2-S?UV8%-(!0@-29&DS63:3482>N2-(!]%HARK6F..<"S+OZ9F<+EG'AE MK@7V;.YSVCI[MH.)AB0):[C.2!8DJQ\XK3M_A>_(R5Z[W.%B$$K(A(\P]%U:;G:>?+G.U=BFU]A6WZZ?0$ MV&E "M*MM6@6>]":&A,8?D;'FJW$B:(%F2.%'DP7(:N>B)2=CH=XX;BO#\/& MHP,@5I\T;1!IK@"?&R>7*Y"L!=WMQ5V8@>NBM,M %/]*WS/3PO7;^JV5*9N9 M?J (2(+Y$>T@2_O'\K.F @_OL"8: G& $0ZTR1MNAHXGQ=$&CIUF0U/28D*V MNI\:[0=)3\^! EJ'Q]FNB-66T"B[$]7I67QC(WDDX^I8H]T1Y@F<;\+K-XA% M.<8X]XY[VP.+JAQ!LYFH)#VE(=331GM0HE1PU$-G),'0(((U<#38@Y^I? MD=6^?KI@/,Q=@!NK0*!%*@1H**P9(/RQZ>^I;36)9F@T:[6TB$:F M-6TT.O( NS]:;BU]L]LFW$TDBXKJ>'U;7A;^<"H8'K.JQLWWCD^;9VXT7'N2 M_#UZ'?Y^&OV^S030S]#Y*$%SU/@K566N&1//+BC<+I'V:$2 M9&=,2!-K!">\#2?"%">?YG"ETYM!IK$I;5 U[58;84Q-AW610 M9)DU4@VL$96LV+//?0[W=($%OQCC(XXR%T #]FYV],6NR58'0X2C=4A-OJ^0LT4SGD7?/'WI#S.?GGCDYGFZ6 =Y9NDZ M@S+-"2YKFX=**5"%UK'1*$]QX1:9/CKM^S;D1 %8,@IF1028SQGK9ENK(^+< M&'BS8H!3I1.*-3-5>7IBG#4@?H*QR]I%TUVOCF]9K/7*ZPKM25U(M3*9PLNP MT]U_>5W.M;P.(/TKE,NE>N_G]55VYQU<.H^)V\?2[]Z?T>/AE-=E_"RONVQ/ MN)^B-GI@8[7K9,#E=4F@YN_AL*J_WI;[_3W?A.F]B@Y<*B5>C_TH%TJ+[^:,!TC41" MYDNOM5C6]S1U&NB5:,3EA^:?V%T&7& ,8)1 "&(T)M%Y'ML16O+]/FM^\-5D M1OW"U$2>GAC%/4:>UK9?3WNN0LP2I>:=M]'2./MA[>-I^K2 Q?X<.3=CW_TU MCV_UB)\C6-D&JZADT>YSKV2G4!;FBC8L$VK$O<86GZUB?J31DRCXH1>DV78N M9_/6AK.@6U>).*SX_[?WILN)(UN[\']'^!X4=;K?4W4*NY@-W6_W%TRV\0 V MX*G^.(00(%M(6(,Q7/V7:V6FE!)BLL'&U14[]M[=!J0<5JYO*#@4^(5JX2&:[RV++$ +?DE.Z&'O MZNK).9*3ZR^[!=;32CE7/3],*6489>CS_/VDD)^4>]G3CG.>^O+O&=0 D9%* M.-0PG-$OH!5 M%W'*[:AV02H?-K= 4<&(6:]&.391=,+09)C%0@/TB(P.-CD M.,)%:H1YDFA5&S2>0!0.- :<0Z'7EI];WP&@OZ2=H"*G$,T(L186-#5XKZG1 M\7%%@D4*'-4D,-^.IKLP:#*SJ1GY$Z"KPF>XQV;H,Q[YTUGX$@^&'AL%519I MH!2/7L\MC4#PMFBN,G I?=0@NIR0"F/ Y"X(C_"MPE@H60,Y,4X,(KD&:,9 M$$76%=;@"E_@B-6T9@.WP!;'#T\4WDY#C9HE?!/@AF#=8)K>PUG%EC@NUB$+ MR7LLL0OAT'SNXHM#CT12XRE#419V=Z@LT3YX*A:X"/YAX\L!930LM.M!ZE#H MEP@P($C2_/7QN*'KMD:5OMIQ=8"7"%T:@&2F$!.R3->P!3I O'Q6\S]R>9%3 MXY5OO9\<)Q-IY?Q,+66@P(*"Y.$+_I)\JD9I3UH>/T_ZR@<#7RYZHL,&(%4N MFM^DKV6@Y]#M;Z^X+9F[#$4!\M F#AW_IY O!=X2\;_X"S#*0FZYVG:FKN)BYGQ23;O923UX5SWU+H*/9 M0UT>_P7M].3!XOI$WF7B2?-4CG?:O*L'?X\+G\&0[FOJJ4N^?5U#K\" $][0$W3HI[VC3LH^-5M6?MU# M!]><:(]%PB7(T(S78/B%7M+P([WS)7I-B&3"IO_S)0BX&/AI4 O2\ (83*"2 MST$EVU(%=/%J8V!S7>(HO6*V?TM,U7G!K<3067X)%@7.EEPB[VX*CS=BG3X=MTHF[@DPMM>\;<=S4ZH#/+W M-YYXS0Z'#99_O2?_M8T+LUVCB=ZFM&!*)M6Q&]'D7D5/+&C:"=NP+BS5JX"K@_[SI:"_K6,XP?\#_)8YQ M4?+&)5$>,6_ 2U@K\P5OD>6TK&Y>Y3E,3.=+Z;P]V:1^"/-@Q7+I*!JL)8S$ M99?N/[QG:U$BP1U+9V/Y;'X3.[:TH[?B);_%IM)VC29:D6=]^WKAA>8K\_M) MLVD::W1LVG?35?5@T3D2TV M$$@1GOT[E/+*K8K[6W7#RA$*M!JAAM4*]2Y3'QCZK/N%";"+]Y/+H>$4ZS4] M4WC83#0E4AW?S"X-X5?S5"'%+ZCG5]NP-=_6R#4]K>XYZ71\?XGPS'_XCE[# MWKWVPEZ\]X34^I_>U5L=LUFFB%7_(5?BB1=3:TJ5)O73P-'LKN4^$R M]SX9K6G'*[F?&08274+)VR)99+]=61_@[Y#Q6U??&)B9_:BYL1G4#-.[L@G- M/77L$XET+)O,Q'+QU0,R.-W7!]'^&QOV)G4]O5WQ>"R93L8RB8/-;)>G/5B3 M"U3D112""T79A>+]Y%A]4.*/V6HAGG];J?4'(1%R#%]]'%FD"G6V(5:\W1VQ M-#54G"L[CJ6U76=.X$AJJXKLVA1LQB36!"W!!6 5*'+=\X8!I9S IH?UH+;T M%3F8_,?M[D!7YC-QQ V'F;_?UE/ ^:YUF06AL-=G-*W0IJ4./%\H?V)(UIFLH(7FM_+-\=$'(1]-6EZ\"%L7L$HBI%Z][Q_C)S.?$ M:IXW:ML"XJS=*Q'%TO>^;N=HLB7 _:QW,3)>>-%L\3NX>H5@;I1"*=U/M&%F M''\P#Q\NY"\2XK']\Z40N*M]+3'5>9Q>M*=+96_7LD[S_ K_YN:+*YO(YXK8B_Z=V^M".:TFOES MM\UG;='-$KD.;PN29&+9U$$LO415V+8:MKX 9[?VXI@EP-VGXW@IKR?[J5]# M@!==%AL0X$0LOQD!WE3EQ-MOD>4Q!#_H(":VYR99#3&2'\P7P]:NZ]6C_%7O M4YR[Z8N#SOM^E6F_Z1RFV^XM%%V&LDW]/B2Z5D#4&PX*IHKF)HNS]Y+":Z9K/ MIJ6E>EN3* H@#+X7DZ%'$E^WRIH]-&U9KW?/3*-W1N2P4T"&LOE82.)]])K' MW4^,\]%3:U![F1CK)_)(WT^2Y;M+W7RTJHD\$'D@+C9G #2[$HQN#XK3 *2D) 6?E$ M(#E;("K;W6F/!5(.[UU!(#E\E?JBJ&K'#F$L,YPD1-$%'"3O@$J1NSZD3':( M8&7ZL#T(GK48L6=?.N;0NA1\B5%TD!<#/)1%)00%@RVQ,!Y'M44R1')[N#IR M"R#1H=53D0'/I]I=+Z[2=(XY$B"S>#^Y;=^=FN/SU,EMYHW:ZBU LHGX3"39 MS/TD,4K?W>:'F6QK>4",M2#))NXGVOGSV5EG-#PJ:5'FT<<@R>;6B21;(C9@ MJ9A4CDNM6MJW 3>#))LD#E,_$7]JW0XN<[FI"/>V(LD2&ZN1&I>RC:ZI9-]$ M""!>G^\)(8O%50VXE^R6>66K5?(HI)HBU^*%!7K(&<^WC I^K>-JSR%K9Y:L MPU[CNMQLK\0S7MWAP-&1BZ+""$I(S$C,8TP=$0O9MG2$)9^)L,/#@'N6ZS#ZB.[ MRM#25$>V@,4**%1-W>R-*>6)9?8L>> !L5YK%HZFI)-K6Z%&4.0PT030@+L. MS3H1N#;$%"$Y^PO6$W&R(I91PR,5*__$/(Q:WH)^Y=T3@MR&MWPP[N M)]6N6GGHC4\S5RJTT+1MS:'B5B:;I9M#W.B2:6^Y [8B[Q@168.Q()$OT'\! M[&@;:!45ES)] L\?K@%U"33V*]1(% 00ZK;,KC-"1G%A2: M6A3/')_5IRSG="W_"$I>/BZ&)TK^&I38LC;9JM94YUZKLH9O#"@FT)H]N^Q9 M\8%[7#7\8AM1>,45QWU=%.>;/X9@ *]@U[L8MDLDUP-XD$G%XKGT5#".$I3] MD=J1[L%N?/IZJZ&")J.DH'@ MP#0009_$G,^(>X=#H7O*?G='U/;L?0.!35BMRRYHY+KJ0X39T7&MO]Y@;,F'YI6V73;#ME[_JU(OH;# (GP M^EYS/RD,6T>/J8OD8T5[R_VX/,'9X?TD=U1KCY[.BT=GV2__>H-$3.4K@U/? M@C3QP4K^G-Z%Y6SC/)\KO+4@DFQ3-BQAB3RJ+)M1U^(M)A(IX2TW\*W.-KD2 MB7*SF8YASQ)"QX[/_AY^*#DE70ALD4NPZ5/.L\@KT+F3^Q_BA$ 2#BJ W%V: MH%2]>3"*>6]:P8"BA^_NC]KW*M1GC:RN0,%D6MZ'?!(04K-4X*2D)&%#1AKB M$:K+/="%_K\*O.H=/PJ)U?AD5+(>D^BT/II:=O,ZC(S>[XD@3I9!_E&A9@G5 M&/.M]&( 1'"U1]U/1L9C[CA9N&O=*6NWU42,2?#G5,F:BA!I# M$+?:7(\6%L&U] @,V&GG[-S(^DV^0%QE2L1'3FS;=?"KE(F F$ ;0'L6?RQUSZ$"XGW9646X#"4Z015QQ@=8@*C8 M@'$9_&\=8E];B@:JXY]'BO&F)L?9JTH5@AA,[L 5B9;P7\S8UJ!=J59O M579W,M*>%-(AR=3]Q,FUSE6G-QEWDRRZN$QP4?*T27N#5LN:\_:+9X?G6+-] M1Z#+>36VODF24@Q[#8DXUYF![#<35Z0$'N)7O?-^\IPZRU1'+[<_BP=S&QV7 MV+5 @^/B[\_I<4R^. "IBJ#@LW-P)_Y&!2D2L7RKB;7::Y M\U: M<5T6WW<1#5M%6<>:AE@HQKGM>"P;[!H]B$=UMAU90&E.Q#BQLA>'@(3JL^-PWS:M$K9&+7X]K!UY<&+\WE:'/K:4';='P(@/' M*P-@AM N4]EM:13;4,M^ ,&+.+CNP&41:2'XN[ \=>UX8.MJ\)PC-,)D"\)< M0U)^F#]_F=0&5]G3OM]#,V.95F-867 8%N#2KSZQ]9R/&?BBN5@Z^4HL-@HV\X-@PY"4@E0E60*Y^9]8 P+7,;+&C.G"-:+$Q#('J\/V,22H3=?[I^\G\2.[YUQ4>O;X M%8[9.U9R?_FWXD77 PE(**0V;)]-TQ(<*"@EB"A;PN^J,C%+>%<98RV#N)VKBLM\[ M33V-LOVUQC=FRILH:]$5U ML#RM[,M&Z* :Z%IRXH@6:XU4_5FEA*#!S;R*8V[@$OJ=?(NJ3>5Z^L[J9.;SO;\CMBQ;1& M9J247LB'+\;DIG^=E44I]4F7-RR9P2%N5B!3J=A!8KJD[Q-HZ$B!3'^40.;7 M(I#0+!91_/CF;/"=%D4Q_A$C"(']UH7R[:LQ\E"2FUB&)AZ9K10IB M^;"L.79O_-1314',?( @PAA_=3EP!5WN.JHUPX_Z9*28Z_"ZF- 58%7F MGHZ.JZ=+[5OY9N K;']!E\ZZO,\9"DQGLP_#ZK,O'*OP98?#U'#73D?4E M3]F6\F:\(;HQU<7%SE#=?>YV\J7 M;*=GO F!ZE5UVZ]''4G,1!U)WD^N)^UB/Y\=WSW+2U]+:T$=*1*W)G=<:%>& ME6HZ]R5".7X,ZDA^G:@CA?N)*A?.7XS#:F+LR\QF4$?@@&0?2C<]N5VHM:>B MNX$5]']5OI_D$P^7M5SN.E6(CK9](![)X9$YNCGOI:V;J1._#@6TD@(XN)]T MZX_E;"/=;&?>VL*S>A_$^OL>@MBSLWH=1(Z;&;^XG]R5BHT[]2)U]+8^RQ5; M&4Q'E;(2]MTD_I[J9TB386FG:;-W<'AI);_\ZX.,X^C#9/"B#0_AEAFA(=P^Y. > =^*+0U6!]Y]ZJ:89C3FUWUJ]B M$%8X='#!C*:#JV*?''3ZTV_;4P6%:Q2#FFGU+HX*H^9QWB^]FN+A108 Z-_# M^P^+9V"\GDQT XLP#(K.7-J]UR[(QPK///8'*C\!!F/:?3PE/!T3VR"A;9A< MT!I1&QWV59\)^9DH5)N7*^WN3#W# R:!RB2;K&L0^! >(6Z22*N,'9H>31WM MSI1<"C#!EWEN5^1J.O.CVMGKAG3B&JI$-@V:"N(!A)3=G:ZF0\^ZYE#(B::J M6(@8A<1M<+IXV9?W+S7U6>[(TE?X(P.TFOZ5AV8E$UN-R'>7HGD"FY@*Y:^T MAD5\1LG_&F*)EOWO>0\SNVP--9^H(UIIL_M4^S=&Y(NC4DVANE1F7D07LE6W M<":=:_@M!TA&+12/9\E5OCZ2@6&GL]P=Y$UEM:MGUF0BE4A\+Y[=(]/;%"O M5;-\(; T1](T4QWBT -YS4FDC^9#Y%/+IMIN-_FWG%3L\5["LT$@-S8(/# Q]PD"+X$ M,FTJ%)9 \2X'BNB\NT.D'."(R#H0*=8,4%ARSY*'?>FK_ V B;ZVOP%$@CF* MT9IB>K[AD$T3+]$#X4./4(-ZMO;O3@)/N71M=%Z *A[+6 MP5-,]G*/(EFC.3=M']#S:R%\@_ IA=SR/T:0)9%+,W3D89B[.Q3.R7;)_P2> M3^?E96!PAHB&C0!.EJK 624:C/Q[]"PE*JG^31M:>R>H!<.7ZB>1SVDX^S<_ MC8BBB-8\_W^7=OV)VB*O=C1%\K?H,V":+'/RJX.!VM&($)%CY'(MH&LV I:8 M70IA%I!NM-@M&?U']GT8T9UI/;)S77FAXBZQ5H2:;'?D)_;AN6P]JDX,$(L\ MS#-JH,,!%IU3_WQR-W66"I'Y!B%PZ;1"F3I9>!>3=Z$>Z+H6'G=VC2%B_%BB M]-?1^HN9)=)74'1D*E,&S#'^F)U?G!C'F4+$O!G?]P[\NB!)R8G@4K764];> MQ"FK#^%/ %2[L4.V35=N00KM/K\V9(08(DJ=HOXRK"&'O% $]J1P^T36R8L- MX2@"#A##&=3(K:&]L )U'T_$_YH'T#GSAM80A90C @OG=&AI&"K!L7G'3W"O MX6JH9Z!5-C R.PD@NN:G 5<2(^RHX_6-Z*X=7 M>(8R8*L@?(!&QH(IA&_=&*"F(LXI>0E I5(FGOE7M_19;V[Q5$_7.(QH!9&' M';;$\2_S.%'@T+-__,07['(KY=]P["KPL$Z!XMW1*? ?11 $<+ GEYP,@#3U MXFLQ"5#&= 9>ZDDR#_',."\Q+OP6$\:P?UJ>Z9_R#2-G!<(.D+>3>^I]9[AI MXM&GZH-VU*E?ITLYSW?E@\%YK.::1L_C8QA"6;'&7E+P6B]T>N8?:4HEJOZ0D=A'MLJ=;R>-=DSX\ ] M1L4H"Y'>66Y8T*=2GZ"KC4CYU\0W>D=!DY\EA'N=R&&W583U)2.)L<. %\#7 MY+?=G:FPX.QP2T@,ROCR]V'2O5-.,PI]8W=GAO3"P]NF M^0@*VAKSJQW^8C.H5 "-#4<.]J6"$X("B@D'CJP4CMQ+FG"S;K8'1(\'O1^F MQ%U$^OMVD.F[0<:W<',"2^2]!FS6"%I M]A9IGE>VG4W$#A+)61*]/W6SBOBN)92LP.&UZ3FY[YB;5C_5=+$P&6LG+U4Q M7QY*CU(3V":;9G=]1SF4#UU:7\V>[X84U)ZM*K"M(SB3JK$X1EPS%R9 J;]! MG(2V"N0'S#F*(C2(6#FG/Y5-]E9O?VOMWDT8_M2!) M, 0\863[<-G$M!23P/G,8@A>-@ _L2VN,^]48@:84?&8W!@>% M6)#XNIAOASF!=/VTVXS>M$]I,">( )\;8B$%-2#IK.&MY'4]%8:SN^,EZI89 M.#EM_E6-_VH:*OL2_!:" &S=(&Q)/@=&0UY(L,3&:/:,Z.3:0G0KE257[B?7 MYY7AU=$@ETV]E0MUA>*W4-W:Z\N#DS/+@W/WDU$Y/V@?)R^3N05E]^LN#SZX MGQSG[+N+NG+4;AQL3WEP(K[.^F B/.JI4:Q?YA1CT-]P?7#\?B+GKG/Y^EB> M'.GSZX.WJ HX?S^9V,:U44D]9._>6%WZ,:R$/H,*0MQ=R 09,F&36V/)?#& M#P($*4L_Y7XR?(X_NNE48W#X^,YUN0?!NMPP($^R<#]Y+G>J!^K516,"7(:, M5PCG)8D3"Q;JKAUL_*,,D0O7 A_8H2%[2>Y9*OH,NSN4.(#6D<43*;SGB" 9 M+.A]XNICB=)OM8I'Z"8#JSPQ!ZSAOL1I#\E'W"^/T2(W0I6C+!OS=?TM/ M-8"RA(QXH!D:L!NBS^J_D3KZ]M T<*J:08P6&!-]*B;[V= ER$U"#2191*!% M'!ET?3'#T1Z3W=9T8G2,R+].8I&&'%+%:0.IU-?4KE1Y41471U,'*FQ(7WIK M9UIT9#+"46*F >G>R"'M!\(<[!7TVT3(3*<_WMTY)F.('@)]]2$GF5C#J_>E MBE>N9;)RQD2:,KXE8[@J$ET48B?J+ME22].!>0,>3]VM4J4.06R/4NR(."3# M&%DN91^'$BC5&@Y-#:,E-5/5I9-]ZR'L%_9E8@Q-X8A_27L1V)%M, MY'1?N@)M0YX#Z'?\X! Q5[&^%394IDDV,K"NB@;E5""FO%BGLCY9&Q2^J)%N MB$$L_B00K9D5%)BEMXMC\1,:)> 5W&0F/"30+#\>-AZ4(_,LY84$#E5:'XUD M9#H>/=SIZ+.Q* +PQD58,DQ IW;OS6P-#'ES"\?V=W>JAE08$B%E2G.$&1S5 MXJ4(H'R)_<12W9XXT>) D"5!8PI,4WQ9)>#=PV,%"5GR75"3QZJLDU^?RF1J M(+AM6^MHLC4.2"[4-,Z0WL"0%DER6@PIJFVG:I"]=^&A%YB2UI0+2A%%21+C M:2:AY)^(48BRZV=MR.\E_P$QB3]"8L]8& V<-X!(&2$"DJ8R@O^4BK^#2)3] MM+T#T#H\)4\OV0CRRVFZ2P8)&$%?*6H6G[6('%9VE-Y#70P,^:E]UJL_&G[W MM,"@!**TYW$Y#O'\+MC8J)E\V)E/SM]A1HXYKQ5JP<8DO(U)K%F/GR?,TZMZ M^TA)O_?&)+R-26QL8\C3YVU,#*CK!*)2T&>!R8H:EJQ%F+G45GV-:4=D;J:( M:B,.;E_N8&\+9CGFOTZ2P06'3\D5242V1W3X.,E?!1S-@HN ZS5Y2XV3.9F_39@+0ELK%T(K6B&LB]8E,H MM?#:-N7".LG5>T_%9BGU09O""(HWH9L/LC%B62RI CZ:"N^=WAIM<+":P=V= M"+LCI+50-.:*,BWC)6]9?)M-^M5<[>GD1KMZ$BXA]G/4H27?I>#RN/@>"KY_ MN3OH[?*63\]M',& @S@U97IJJ.Y')I)=RP8D'F@2!9,1&!=HCQD%G#4@%\L0 MO-T.1BC(!=9R+>-1):YL\,!B.01Y 1?YE4!S-BW&5GF2;MM)ZY/SCJG6N*= M]RXRX+E<1G?.]AFST[J8+ *+J#/O]$0:[>M*!GV,MFBD1.K6L[.2%]9KI+RH M'I$]+IKGUKY$8T3,4;4%DE.B1^076AYFFH^/JCH48W3I5O MM*U1ET;*7WRR]OS.+J2+=XEC8W@R2O\*$9C(66[< 9 B+;+41J1BO3[<#*E( MG5ZEK=.NXA3E3R05,UW!#4G% 1&*U,R"V9@4= H%)XQH0KY._Q%+L27H459= M#G49IN5(P"&_NZ/(=A\R-LABR*]&V$FI2S:76R.,A)Y_#2R9CHL1_8Y*1HK% MZ=A-"2S7F"TP&:6V3.LZ-(R1VLXOL.SAS%O(T9*^LLO2A@ L9M7QN&*)M?^U M;[L[6/#OFW@:6]AU$_!LD&N'*Q6!X8;-G55O%HQ.@4[\3)/;FH[-MF_EULF) MD;>WO/I^,CQ6]8K:'9<:F?E,.C/SR=O#>R/@C$X1UAS<3Q[=GJV\C(YO5!\? M;PYAS?"58BU-2W4(C#0:+Y3,'+[USY=D)&I<)/G,4EC7;W[PTF"P$4"O*S A MYCPBM)$*8X*GZIU0*<,<5KW<:D24$$]O_%AQ> MGR%MY/F>&[+9UU!>8%YAMQHU9&XX$Y7WMPRLX_EBF'_C8I!8FQB\$Z=S-AO% MT-PJ'BW/!#P?)_J5O)V%8+M71-Q]C3D07AL%I5$<7B>0[EX4\Z?S0)B1O=J[H,]&5$[U* MG>X%%,IO5JA+4;.%O"I!3(EE[R4W:SR[V='6IW'I*GA-M/I=<1(WM=O$@\A$ MOM@EF:J 6&J)EJ,A7V9UEE+%XES??A RZ7PLD8D*FRX@Y9X6DF\?)H6%-TOA M6K1O4 KC#:O2?C3TL[SV"TAA6"UONQ1NVMI=2%*/OE1CBC-SN=^]A9'H+0R5LF?AG MMN(>F2'^9[>6*IL=YT+Y+XA_Z+[95-(X]Q[B_RX,?-,,6ZLY?.*%F E>E.%?83K+R?\JTUDWR1?T1?WS96]* MY1\D8P>YU(74:@[,?5KIRM7#TK%]J\HCDPMKU$< MD_D$,?W?01S#1'3AQNNU9<]#.?3-]79G66LV2&BI?_IW#SM/TH,PO7$OIR[9:X-TE M92)EEH;@N_QN#=8 7U[:!Q7WXOFN[-< ^\^3ANR!8G=AQW_FE^6$/Q4H&PP) M^S)C__)OU=C=H:E:VCP ^A"Q_ !U@E76*,\!/'^'3$UC: M_2-+75D1N6_8TT5AQMY1-IW=G50F+C$8+Q_GELB'^J):BF8#_)1&8?[_2.R3 M[_J<',2'T"R&*4Q[65-Q+,$]V)]2;*S04L07"#=*!]NA;.@_$#:#EOV*)$M$ M>KRSBF1,,)2I*LY" #Y-U%_.+$JI,]/H054;? > 5T*1/!B(\*0S4S9\K<$= MLI_Y7-[HR?9YO1M)G*&37RU&/PL,=ZD \!*#6_Y^#MF&F07MC50 #:](;R98 M;&)F;W"5_10@*;V.?P$UENQ89WCO M;IQK;.=1*=3&-R^]3SBV>KXI16ZS9> M,*5WWM57P\<"]H;C\N.^?+?W.?[*&9?)]"/OC?5NWGGW]G'2?KP[&AP(C2AT M"(AF_JI[YO4; :_$7H6./!ZK1&L:X:+'V(TGZ9@"6$NT_I42+,[=76 Q*- 6718LX'#VR&Y%FPLU#HEIK%LP7)5HS MTE%XM\QJAVW><&9U(H1-BC?BU2;WY^E(;UYTP\1-&L@A3@H1TI\RQ 10:A&; MWP?S#N\W)O*)$;'!4NDO:Z5;>,]GK]'L]OS*0$'WC/?"GN_N>/1 %#)P)-AE MLO+D:A9PDGD03,1"ZL%6AP]E7+1L**8KL_#J%J)DSB11G4R*$RUYWCJH/OI0 MKE4N5T0A\!$MM% 6O'8-4:MHV-5$YB"664S,M036Y6QK=^7UKK!GH-+Q/K39 MIW8BM E/)_7QS^1-QVGX.>!*8!BO6OY%HUC[GHC*#SR$I90?(IZRL8%OQ-8? M\Q2LK96[/-/D)3YU'^,GL4RW1]VPKM9U^GMCVB]B: !%"AQ^# ETH[KP(W5* M5]8XQ2417>15&WF+BTHFW*U*[+DY+92(S4:>/\!HI,@90Q[OW4" U$8?B2%) M:*(P=3AVZ&GO@0S#%P9F1]5]9D6?889(KSO [ZZI1P7_DQHJR^W0)AM8\$ 4 MB8/=82A#!;(?%'::$AC9P,.)(:R"OPIO;FDI1[:TK&,P]Y/Z>3*1ZE6,_*DZ MM\EE^:C:FYI>&/8HA''_0FJA9?I@,O$_O5]:M#T"?KID:TQ4"LZ!2/E0QESE M=&(BVK )==44[B?CXFU9*:H795->IJM&.#A+=<5$C&9>.>S"QI;E'DB#ZALN M*<\=_#GCM%-D9KQ(9U9N+EW>NURV2*0-P4.'EW#HWD_>RC_5T3#?3X18/.B= M/P6!^V=D,F>^9>"_?*/7?7P_O;@N:^XJKJTJ]A7G,&ALO?($+4H:^KH7K%#5 ML*F:!05((9Z*XVCU?$BN=.1J%E1RP+8+B=7#8<4,!7I7,8Z:Q*L0:EX=K$WN)V8Z6XNE_,^/4KJ J:#Z5#[2 M&%#8WUNVLYM3T71^(KD6D>UH2)A)1^X?&O5BZ_"H*RCMR!5Z9QT]/8O7"?=$ MM&G3$G[M36VN_JY4 M'3>5.E%4.4+$PXOT(4(>G,C[ZO!<8C\^$Y5P^Y6XKG7A#I8@X&9_N YO+Q:, M]BJ"T5*M0>*^X]Q%2_9%UFCT7XX/.R-Y6K(#*[-DTG$QD%W'M>"!4W&GC5(W=%L9EU8 X0%05MX!'5&5R2H'/ C\UN[L[\$>>?-F7 M/&'R%23$RKU']#6(C\,I%[^!)%R8\/B_P50'33E:GNV,Y1D "48A"RG;/:T^ MVMT!"05U!"1?;'B2.+K 0."#J_TF>8&ERC:146JR2(IK/>,IH!%[3B*,&4TA MD$P'%C1WA!C7[D[X7?[\Z *CN,,3O6<,J9!O$I_K8R6+N!RN[J!(R:'P?U3Z MGE=1> ?>RPQ%Z[:#4JEQ=?5H'%WJL^YD++J;?MXF[L\9P:=$=NKFA)I:U$V0 M:^(I$"+B4VM2\M>DP%.LC,8W&%8+@YP+LT$H6!A7[9^6TV30$5$+_C7Q8M'9QQ>*XJ-=O9 M2L=Q*) Y[%!4V M*LL6+'DDTR;3F43ADXK+7J!?0XU7[\+48<:P8A>6.M#<0?1YSBKU@Z-Q8E"I MRXM6=N$;UGS"I]8XFYL'U<_NH0YP@G38P"BI$HL$L=:V_9E%]D*->R)[/QG( MZ>;5[6&K<919%Y';I@@?R5/GL2:F0JR)2[;RO8$;<;J'YX,8$!-O9T#DJ[5& MGL-P*N==V0R9P&R"=W0=W,!P!N7[>#SKTX:V_ZVV*N=2Q0T+\;'?'_Q#UOFO; MC+,76'JABLM2$2Q6\(J 2)L\JJ@JLFO#A:R.O=]V7>R:4)_QB108F;);V;$Y M X,Z:,"A19)."5'E*20\,:P8'#HQ.35%&Y)?Q!@N.O^DK>H:>6'XS[S2)OQW MN-*,3OBOY,;3O3_N[K"_VGWQS_R[HZ@_D@F$_V2KZF/X;T.=;'+XIQ")F7J) MINM3XZ&.V=0SB9&G1?W9?(CX-JA@1;:GOVXZP'XCZ]-+ TW@KNH-Q@ [F%BV M'A6N.+\?VD%P5Q"?5QXS/7:R2$KY( MK!803L^%?9:)O^W:K'5M'"J%HGP0M/U=]&_)!VW3I1XT$U[LZ&=BWW-E<'94 ME4RF"0(IS$ SGDW]F7CUCX8Y,O!GKD'_&<(!-N N*\2:!C),C17IF+!B>(), M?L) \NE) CHY%AR@CBAYA ZTFEB= K5YFC..06 !34 L*X5?]$'\*8LF,=G: MJD>[JB(=F5R?D<$^-O/&B; M>C0D7R[UMQB$G/6"?"+R#>+#4)3;-'3FF!)7(<@9+_5,$!WR-W(ZC%@@[+E$ MS#VX1)$+LN;I+S%7>CUBF)#XR;9'*S/BT4IQ%3[_E$&-B!RS?F>D[N-Y(PK] M-.+TYY]]2+@M&8J!;!?X>#70M(H\U!RBQ,EG71>4OFLQOJ'Q+S=YL*9Z&//& M)@M;\V];[+<5+I@N[\/H^.Q+GW\]8)8ZL7T0=R<$4X MS?8O(Q^>&4ETG_P(G.,JW/RX&AA- IY;S(.8Q*YY!FO(H[2FAAU8 Y]^&8BM M UD;E'7;F;)@_*E*)MG_'K=%[5]0(F3O?# &>,B.,9TH= P9'?H]MA342H4% M0L-UZOMM%3[K(!/WB\C-^BE3VEFZL=K3]1X[5-Z=X6LYJ\Z87(B?"6#S=!X3:L )2,['E[+ M. ;V#>U'(@N#'T%87^DCJ]0ONCBE^G6UO)?(1T^/90VV/U!\9[H2#6:2BU4& MV]S$]DY]'(B]<;.]8RHN"\QBC&H$4:,N!&;@1%@J@/3P/#?&VSRMBE\7 EDL MIL9C3JP=?W: BCSF!S$/1N1F@]"R#&A LK.[XSG2^]*-*CV11VO=L42>P%7[ M[,@4:WTESU-D%XP+Z%WU/XZQN!0=O6G#Z#IJ*"H)7T*6G]V=ZKY4)3^5$H5] M"A:9'?Q?=.T02"Q<.>6IK&GN(R MIP%#N+5HT% #+![;6_C='0$'"KY:>5'Z4)J&P$,:AF#W)>2*AB/LN1SB?O.( M'(2W<&5T+S9)XQ<8%@=N.;+%*MDMC=BD"MW@-C2J$O.>4F_[1KP0GMQ'>86# MY3V6K+G58^!\6+$$*$2(Q4 >HF'7,L1=B9ZQL@9@ ?=Q=_P@=C&H&92&Q3R/EA[V'"P 5BX?BV.6%6LLWJT#>B38.&TT0W M M^'%1O^4=O=T0Q:.0#CQD.+DSU4R3^1;1-0N71Y1*8S8D?;D1\A%BZ\@ 5U MP+UAS@K$ZI'$\%FS^0CFSR/&*/90#/UTD?\W])45&K&G_K1K^#F@#OL-%KG9 MZKS3OS"? /M$SSC(X-C7E""(%D@]+9"S Y%K;EW+NHV1/6")]HI4V%V"ED0@ M!1"Z7<)/I6=)E,FM9S?VN,<*Q4^4WK_RM#A6@+"7(RTP[5ATP ** ^3N_:.14P:HK'[ MJK&[X]K3.54LG%.M@9=-/R?WYRU7*P9]QE/#= 2>(1D<0TRJ&LH^T<%DM9[ECDSF90T9'FF,60=@E9AD M$?8H';KMMHG6U63P;[=03W[Y]ZA2JS0*9]LWM-E\Q#Z.R+EG<7D0/V5:Y0$F M &Q(@=B+8QLN4,Y9?U[^'WDP_+O F>O!G*/U%I3CN:_J0Y:#EL$ \7V'2$BA MZ$QUT-ST"DSV=W=@ GP(\.JA94+E.HL-VNYPJ',3DHH4N^C;=$!P:LCC'LB= MC6:.X.+(Q#]P,)@+2T;#N@;>3GB9^\,)W^48PU-8+!>6E1@5JI<*]P_JI4N< M"ZA;B' 7+K=0N&=+D+@!7G$&F#2+5G%W)VH98\P([\O/*MDHU:#LMQ8SELG2 M6ATLA:#!&X^S +KSR;.& )W34PVP<<$"5,!X]O%@KPP<4!->AW)6P')6V1?I MHT+A@HLS;:F@[_?L?VK#O4I$B-1A0LR67#29!V!J\[HE%/3=G0>WTZ-?IO58 MM.>#GB$0%*^VVV88)BJ6C0AI6!!#CYD"_H4G9#L^P SB%>*ZP?&@3V$A>>]! M^X#PZWEAL+4VZF1_P,'N&2$;AE:M7Z)#'5JQ.L>K-6/%7*@MZ+&TB5L*IHSG MLNSN*)JEN /0&PK(9JBHA#RQ:EY8 MRO B!*KBP'.0.QK(U9#V^K%D!76ZB= #F;U4"-3TH)_(W$%>DV.+VTXGZL=% MQ'4*5-1MH5KX\F_]NM*XKE9NMF]L*Q#31YDFTM=ZJW19_.N\?'OV#;NG$)77 M,)]1%>QU+(VXI.1Q2M\P=;,WYAD\@(4>$E>\ZV*\"S-6<&KA_G$L5X$ &52< M0?LH^5@'?#6JP,P.^92*H*U:SYJ"H,ST%@7E K7WY)XAGKAEQ+#XOZ/2BVTH MH_/-PM<0O49@;7G,!!B&QNY"VJ="GM;7ACRZ9+D(FMTQ,;1!U1X+*<'1""X/ M*'K'A+/P;.H88"-^%IZJ 41IB.23U24/M,9[>]H [F05\PFN03ZDYAV[J,F) M=Q"1TU]#G#NYN+$RD*T!FR+[S<"T$+R.%E_$H,G.=O9\-#MA"7C4C:_=9^EC M\Q[6_O<(@STE6COUF7R9&Y5>X>12=C']9!!'AM5*@;8=DOU\00U(#LD?R=Q^ M'N TZB)RMP24"_S.D\2>&31CL_&&=F,Q\ZK**@XXZ5'$D4&M(+B<$/V' M6E7ND/5M0@!2XF%Z$'-_ROB=J8H=6ID T3K5@,M.UJ'RDI8ER!K"#PH!88B& MTJ(-5M9$AF2H*IDRM;AMU0^!"C6%^JTUV9 M:U<%:]E-C-YY\6UH!>O T11,*2R[YBV?7G4L&1I13GZQL1_ &Z. 62J[_?%> MMM $@87G>53;)2:F;1-E#Q%7FD7M@L..JIM:HHZP^$20F,B2 ]#5:-@F6)>[ MH(#2ITS F"CC/, 8/G@WY'XP:9F^!J+J:'@7P%=X69)0G[:5)@51>PW?O*M[ M:[.=Z@\Z 9=G5T'P<^D>8/),I>W+;,2)[^S/IB0)']/7JS[SIL(!,E,Y 2&^$ M#HE$D0;5@>8E#=6N">1Y3C/,DN=ZN6:8Q6C"2_7)4!TTHX HF@SJ)#>].E^)'XO^X3?IQR86:.OE M;^,K#%K\M^A%+TSB]\)$+$R5A6P^]#R^$L\S5&>[<,X4XJX>-I0V#8/X&BC^ MWZ/9$,3W+ 9VSC>1^W,I&N(+R^Q2* *H:U55.SP% 40_JI!\&0J#)8;QQZS7 M+OP]6_]4,A?+9@Z6'_TB3H#/MP*I?"P# %:?=07FOWO99?B:B,?RP%;XEF4( MDW._E]Y?XGQZ'-,!QO8YE_CB;7KUWBRS'XDD(V]=X:^T MJ%XT>6L7/Y9)YF/Y3/H7%*QLG,PN\RL>F3PQU=/QM^[9QUPQ,V(?O(-0UQ&F MB]72TAHLN3/0#,UV+,2#6SCKY6,KJ\=35MO+-SV8G]!\/I;*3UD2BX(R;Q2Z M7VP-B4<3<5Y^K^$*:YC+Q?+YC2SA-L8&IWU8^E$CAAN^44B@8_>Y+GZ]$N9B*52F5CF8&&^YO=2 M+E[*>(Y(9FHJC+F>I5RKR;3%J(S-"*J%L6H12^V] M2G)HI@O>OKL[_M"A#U,C4X8^*0H)NJ&2I;<]C$VJH_J3&DX%J($(B ;AA4G1 M$G*H1;?, :6;XOPC@,R&>!0>')>&;7_$9=(4VBTH8-IU:7L7![[S>GZB-Y3O M2<2V)FAIOJ5*(Y46JR-Z,X["(XAZQ7.3^](V;EUR>NN6S"W@AM*(,+9T\0_A M,.33$/V"AU'<0NR+,#KB#G$ACPE+"0*PU![%L)9[9/IHJ!QO!AHRL<.=(A=A M+R/QP0&76^LP&+^6:QF/ZEB2@Q/B/0HCV08L'(;:38;SFKU&>H$1HJ9T 7>@ M/184D= \XPFJUW!-OME(;64S06I:=PT"D75;VHN0$18+!6U&=1BT=XMM,IS: M3<*:#>PP!@ A:*II%8\H:!%K6/-?)W;U07UH-+S!."8=4QBZ4]D:R-B.^ J! M2PJRX:D$;]BOT#';N+WIZ>T=SHS^XLZRD)V_LUQI[^XLK[75P5 WQV357J^S M_>V94MF@FEZML[=SGS*A?8*=H($,[$A:.N:(6IOM&_;C^OONP7IU@$/!'.*) M@R?XZMP3A%?LUO:MZLQF%09![\U6[ *4L7MM $VY#$0+E=;N3M>U,&@S:-@&/P)GBS!O1CB9BVZ9B>6KTX -@ M$:%1=V1:B)W %[2CPHL<>C62B_$@EDJDMU FHE?V<+KI8MY1CR'\)':SHO^5 M.*"V /:,VK).KPBXOV==$0A?Q%0XP]K@/(O(N4;3[$)-=:B0<<0J/W;+R&[ )*:+,M4<$^W,@F4#&Y0\B.52N1@HMY!_ MF\QG8XEQE^#6*W M#.4Q-MS@#:B0Y",;N3@ '%%KUB3ZT*=Y0\)BS%:0(% $H M[?=;N0V\8"GXQNQ_MV\T_;MO=%/PC9L3]?6;ETOW]=.JB9+I\[W7?8!>KRG_ M\QBC-=-0M]"R6'%3NMV]HJSC9=CLJ^1*+@"7.0W&;&Q7WL/#8W@GB+ #7@&Q M./;:;*8VSE069HKX)[L[^&U@$+0$H+6QI&N/@,$#0%/X.(\VD7R5\WM2%#H& M+A,!QAACIA(:.9&?

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end